<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0112211406
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Darista
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DARUNAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1080.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APL Health Care Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APL Health Care Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QJ05AE10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is Darista ?</strong></p><p>Darista contains the active substance darunavir. Darista is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection. It belongs to a group of medicines called protease inhibitors. Darista works by reducing the amount of HIV in your body. This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection.</p><p><strong>What it is used for?</strong></p><p>Darista 600 is used to treat adults and children of 3 years of age and above, at least 15 kg body weight who are infected by HIV and who have already used other antiretroviral medicines.</p><p>Darista 400 is used to treat adults and children of 3 years of age and above, at least 40 kg body weight) who are infected by HIV and</p><p>- who have not used antiretroviral medicines before.</p><p>- in certain patients who have used antiretroviral medicines before (your doctor will determine this).</p><p>&nbsp;</p><p>darunavir&nbsp;must be taken in combination with a low dose of cobicistat or ritonavir and other anti-HIV medicines. Your doctor will discuss with you which combination of medicines is best for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Darista</strong></p><p>- if you are <strong>allergic </strong>to darunavir or any of the other ingredients of &nbsp;this medicine (listed in section 6) or to cobicistat or ritonavir.</p><p>- if you have <strong>severe liver problems</strong>. Ask your doctor if you are unsure about the severity of your liver disease. Some additional tests might be necessary.</p><p>&nbsp;</p><p><strong>Do not combine Darista&nbsp;with any of the following medicines </strong></p><p>If you are taking any of these, ask your doctor about switching to another medicine.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicine</strong></p></td><td style="vertical-align:top"><p><strong>Purpose of the medicine</strong></p></td></tr><tr><td><p><em>Avanafil</em></p></td><td><p>to treat erectile dysfunction</p></td></tr><tr><td><p><em>Astemizole </em>or <em>terfenadine</em></p></td><td><p>to treat allergy symptoms</p></td></tr><tr><td><p><em>Triazolam </em>and <em>oral (</em>taken by mouth<em>) midazolam</em></p></td><td><p>to help you sleep and/or relieve anxiety</p></td></tr><tr><td><p><em>Cisapride </em></p></td><td><p>to treat some stomach conditions</p></td></tr><tr><td><p><em>Colchicine </em>(if you have kidney and/or liver problems)</p></td><td><p>to treat gout or familial Mediterranean fever</p></td></tr><tr><td><p><em>Lurasidone, pimozide, quetiapine </em>or <em>sertindole </em></p></td><td><p>to treat psychiatric conditions</p></td></tr><tr><td><p><em>Ergot alkaloids </em>like <em>ergotamine</em>, <em>dihydroergotamine</em>, <em>ergometrine </em>and <em>methylergonovine </em></p></td><td><p>to treat migraine headaches</p></td></tr><tr><td><p><em>Amiodarone, bepridil, dronedarone, quinidine, ranolazine </em></p></td><td><p>to treat certain heart disorders e.g. abnormal heart beat</p></td></tr><tr><td><p><em>Lovastatin</em>, <em>simvastatin and lomitapide </em></p></td><td><p>to lower cholesterol levels</p></td></tr><tr><td><p><em>Rifampicin </em></p></td><td><p>to treat some infections such as tuberculosis</p></td></tr><tr><td><p>The combination product <em>lopinavir/ritonavir </em></p></td><td><p>this anti-HIV medicine belongs to the same class as DARISTA</p></td></tr><tr><td><p><em>Elbasvir/grazoprevir </em></p></td><td><p>to treat hepatitis C infection</p></td></tr><tr><td><p><em>Alfuzosin </em></p></td><td><p>to treat enlarged prostate</p></td></tr><tr><td><p><em>Sildenafil </em></p></td><td><p>to treat high blood pressure in the pulmonary circulation</p></td></tr><tr><td><p><em>Dabigatran</em>, <em>ticagrelor </em></p></td><td><p>to help stop the clumping of platelets in the treatment of patients with a history of a heart attack</p></td></tr></tbody></table><p>&nbsp;</p><p>Do not combine Darista with products that contain St John&rsquo;s wort <em>(Hypericum perforatum)</em>.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Darista .</p><p>Darista is not a cure for HIV infection. You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your physician the precautions needed to avoid infecting other people.</p><p>People taking Darista may still develop infections or other illnesses associated with HIV infection. You must keep in regular contact with your doctor.</p><p>People taking Darista may develop a skin rash. Infrequently a rash may become severe or potentially life-threatening. Please contact your doctor whenever you develop a rash.</p><p>In patients taking Darista and raltegravir (for HIV infection), rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately.</p><p>&nbsp;</p><p><strong>Tell your doctor about your situation BEFORE and DURING your treatment </strong></p><p>Make sure that you check the following points and tell your doctor if any of these apply to you.</p><p>- Tell your doctor if you have had <strong>problems with your liver </strong>before, including hepatitis B or C infection. Your doctor may evaluate how severe your liver disease is before deciding if you can take Darista .</p><p>- Tell your doctor if you have <strong>diabetes</strong>. Darista might increase sugar levels in the blood.</p><p>- Tell your doctor immediately if you notice any <strong>symptoms of infection </strong>(for example enlarged lymph nodes and fever). In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body&rsquo;s immune response, enabling the body to fight infections that may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body&rsquo;s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.</p><p>- In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>- Tell your doctor if you have <strong>haemophilia</strong>. Darista might increase the risk of bleeding.</p><p>- Tell your doctor if you are <strong>allergic to sulphonamides </strong>(e.g. used to treat certain infections).</p><p>- Tell your doctor if you notice any <strong>musculoskeletal problems</strong>. Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.</p><p>&nbsp;</p><p><strong>Elderly </strong></p><p>Darista has only been used in limited numbers of patients 65 years or older. If you belong to this age group, please discuss with your doctor if you can use Darista .</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Darista is not for use in children younger than 3 years of age or weighing less than 15 kilograms.</p><p>&nbsp;</p><p><strong>Other medicines and Darista </strong><strong> </strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.</p><p>There are some medicines that <strong>you must not combine </strong>with Darista . These are mentioned above under the heading &lsquo;Do not combine Darista with any of the following medicines:&rsquo;</p><p>In most cases, Darista can be combined with anti-HIV medicines belonging to another class [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)]. Darista with cobicistat or ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs. In some cases dosage of other medicines might need to be changed. Therefore always tell your doctor if you take other anti-HIV medicines and follow your doctor&rsquo;s instruction carefully on which medicines can be combined.</p><p>&nbsp;</p><p>The effects of Darista might be reduced if you take any of the following products. Tell your doctor if you take:</p><p>- <em>Phenobarbital, phenytoin </em>(to prevent seizures)</p><p>- <em>Dexamethasone </em>(corticosteroid)</p><p>- <em>Efavirenz </em>(HIV infection)</p><p>- <em>Boceprevir </em>(hepatitis C infection)</p><p>- <em>Rifapentine, rifabutin </em>(medicines to treat some infections such as tuberculosis)</p><p>- <em>Saquinavir </em>(HIV infection).</p><p>&nbsp;</p><p>The effects of other medicines might be influenced if you take Darista . Tell your doctor if you take:</p><p>- <em>Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine</em>, <em>propafenone</em>, <em>timolol, verapamil </em>(for heart disease) as the therapeutic effect or side effects of these medicines may be increased.</p><p>&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; <em>Apixaban, edoxaban, rivaroxaban, warfarin </em>(to reduce clotting of the blood) as their therapeutic effect or side effects may be altered; your doctor may have to check your blood.</p><p>- Oestrogen-based hormonal contraceptives and hormonal replacement therapy. DARISTA might reduce its effectiveness. When used for birth control, alternative methods of non-hormonal contraception are recommended.</p><p>- &nbsp;<em>Ethinylestradiol/drospirenone</em>. DARISTA might increase the risk for elevated potassium levels by drospirenone.</p><p>- <em>Atorvastatin, pravastatin, rosuvastatin </em>(to lower cholesterol levels). The risk of muscle damage might be increased. Your doctor will evaluate which cholesterol lowering regimen is best for your specific situation.</p><p>- <em>Clarithromycin </em>(antibiotic)</p><p>- <em>Ciclosporin, everolimus, tacrolimus, sirolimus </em>(for dampening down your immune system) as the therapeutic effect or side effects of these medicines might be increased. Your doctor might want to do some additional tests.</p><p>- <em>Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone</em>. These medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory conditions of the eyes, joints and muscles and other inflammatory conditions. If alternatives cannot be used, its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects.</p><p>- <em>Buprenorphine/naloxone </em>(medicines to treat opioid dependence)</p><p>- <em>Salmeterol </em>(medicine to treat asthma)</p><p>- <em>Artemether/lumefantrine </em>(a combination medicine to treat malaria)</p><p>- <em>Dasatinib, everolimus, nilotinib, vinblastine, vincristine </em>(to treat cancer)</p><p>- <em>Sildenafil, tadalafil, vardenafil </em>(for erectile dysfunction or to treat a heart and lung disorder called pulmonary arterial hypertension)</p><p>- <em>Glecaprevir/pibrentasvir</em>, <em>simeprevir </em>(to treat hepatitis C infection)</p><p>- <em>Fentanyl, oxycodone, tramadol </em>(to treat pain).</p><p>The dosage of other medicines might need to be changed since either their own or Darista`s therapeutic effect or side effects may be influenced when combined.</p><p>Tell your doctor if you take:</p><p>- <em>Alfentanil </em>(injectable strong and short-acting painkiller that is used for surgical procedures)</p><p>- <em>Digoxin </em>(to treat certain heart disorders)</p><p>- <em>Clarithromycin </em>(antibiotic)</p><p>- <em>Itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole </em>(to treat fungal infections). Voriconazole should only be taken after medical evaluation.</p><p>- <em>Rifabutin </em>(against bacterial infections)</p><p>- <em>Sildenafil, vardenafil, tadalafil </em>(for erectile dysfunction or high blood pressure in the pulmonary circulation)</p><p>- <em>Amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone </em>(to treat depression and anxiety)</p><p>- <em>Maraviroc </em>(to treat HIV infection)</p><p>- <em>Methadone </em>(to treat opiate dependance)</p><p>- <em>Carbamazepine, clonazepam </em>(to prevent seizures or to treat certain types of nerve pain)</p><p>- <em>Colchicine </em>(to treat gout or familial Mediterranean fever)</p><p>- <em>Bosentan </em>(to treat high blood pressure in the pulmonary circulation)</p><p>- <em>Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam when used asinjection, &nbsp;&nbsp;&nbsp;&nbsp;zoldipem </em>(sedative agents)</p><p>- <em>Perphenazine, risperidone, thioridazine </em>(to treat psychiatric conditions)</p><p>- <em>Metformin </em>(to treat type 2 diabetes).</p><p>&nbsp;</p><p>This is <strong>not </strong>a complete list of medicines. Tell your healthcare provider about <strong><em>all </em></strong>medicines that you are taking.</p><p><strong>Darista </strong><strong>with food and drink </strong></p><p>See section 3 &lsquo;How to take Darista .&rsquo;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Tell your doctor immediately if you are pregnant, planning to become pregnant or if you are breast feeding. Pregnant or breast-feeding mothers should not take Darista with ritonavir unless specifically directed by the doctor. <u>Pregnant or breast-feeding mothers should not take Darista </u><u>with cobicistat.</u></p><p>It is recommended that HIV infected women must not breast-feed their infants because of both the possibility of your baby becoming infected with HIV through your breast milk and because of the unknown effects of the medicine on your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Do not operate machines or drive if you feel dizzy after taking Darista .</p><p><strong>&nbsp;</strong></p><p><strong>Darista </strong><strong>contain sunset yellow FCF (E110) </strong>which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>Even if you feel better, do not stop taking Darista and ritonavir without talking to your doctor.</p><p>After therapy has been initiated, the dose or dosage form must not be changed or therapy must not be stopped without instruction of the doctor.</p><p>&nbsp;</p><p>Darista 400 mg tablets are only to be used to construct the once daily 800 mg regimen.</p><p>&nbsp;</p><p><strong>Dose for adults who have not taken antiretroviral medicines before (your doctor will determine this) </strong></p><p>You will require a different dose of Darista which cannot be administered with these 600 mg tablets. Other strengths of Darista are available.</p><p>The usual dose of Darista is 800 mg (2 tablets containing 400 mg of Darista or 1 tablet containing 800 mg of Darista ) once daily</p><p>You must take Darista every day and always in combination with 150 mg of cobicistat or&nbsp; 100 mg of ritonavir and with food. Darista cannot work properly without cobicistat or ritonavir and food. You must eat a meal or a snack within 30 minutes prior to taking your Darista and cobicistat or ritonavir. The type of food is not important. Even if you feel better, do not stop taking Darista and cobicistat or ritonavir without talking to your doctor.</p><p>&nbsp;</p><p><strong>Instructions for adults </strong></p><p>- Take two 400 mg tablets at the same time, once a day, every day.</p><p>- Take Darista always together with 150 mg of cobicistat or 100 mg of ritonavir.</p><p>- Take Darista with food.</p><p>- Swallow the tablets with a drink such as water or milk.</p><p>- Take your other HIV medicines used in combination with Darista and cobicistat or ritonavir as recommended by your doctor.</p><p>&nbsp;</p><p><strong>Dose for adults who have taken antiretroviral medicines before (your doctor will determine this) </strong></p><p>The dose is either:</p><p>- 600 mg Darista (1 tablet containing 600 mg of Darista ) together with 100 mg ritonavir twice daily.</p><p>OR</p><p>- 800 mg Darista (2 tablets containing 400 mg of Darista or 1 tablet containing 800 mg of Darista ) together with 100 mg ritonavir once daily. Darista 400 mg and 800 mg tablets are only to be used to construct the once daily 800 mg regimen.</p><p>Please discuss with your doctor which dose is right for you.</p><p>&nbsp;</p><p><strong>Instructions for adults </strong></p><p>Take Darista always together with ritonavir. Darista cannot work properly without ritonavir.</p><p>- In the morning, take one 600 milligram Darista together with 100 mg ritonavir.</p><p>- In the evening, take one 600 milligram Darista tablet together with 100 mg ritonavir.</p><p>- Take Darista with food. Darista cannot work properly without food. The type of food is &nbsp;not important.</p><p>- Swallow the tablets with a drink such as water or milk.</p><p>&nbsp;</p><p><strong>Dose for children of 3 years of age and above, weighing at least 15 kilograms who have not taken antiretroviral medicines before (your child&rsquo;s doctor will determine this) </strong></p><p>&nbsp;</p><p>The doctor will work out the right once daily dose based on the weight of the child (see table below). This dose must not exceed the recommended adult dose, which is 800 milligram Darista together with 100 milligram ritonavir once a day.</p><p>The doctor will inform you on how much Darista tablets and how much ritonavir (capsules, tablets or solution) the child must take.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Weight</strong></p></td><td><p><strong>One DARISTA dose is</strong></p></td><td><p><strong>One ritonavir</strong><sup>a</sup><strong> dose is</strong></p></td></tr><tr><td><p>between 15 and 30 kilograms</p></td><td><p>600 milligram</p></td><td><p>100 milligram</p></td></tr><tr><td><p>between 30 and 40 kilograms</p></td><td><p>675 milligram</p></td><td><p>100 milligram</p></td></tr><tr><td><p>More than 40 kilogram</p></td><td><p>800 milligram</p></td><td><p>100 milligram</p></td></tr></tbody></table><p>&nbsp;</p><p>a - ritonavir oral solution: 80 milligram per milliliter</p><p>&nbsp;</p><p><strong>Dose for children of 3 years of age and above, weighing at least 15 kilograms who have taken antiretroviral medicines before (your child&rsquo;s doctor will determine this) </strong></p><p>The doctor will work out the right dose based on the weight of the child (see table below). The doctor will determine if once daily dosing or twice daily dosing is appropriate for the child. This dose must not exceed the recommended adult dose, which is 600 milligram Darista together with 100 milligram of ritonavir two times per day or 800 milligram Darista together with 100 milligram ritonavir once a day. The doctor will inform you on how many Darista tablets and how much ritonavir (capsules, tablets or solution) the child must take. Tablets of lower strengths are available to construct the appropriate dosing regimen.</p><p>&nbsp;</p><p>Twice daily dosing</p><table border="1" cellspacing="0" cellpadding="0" style="width:697px"><tbody><tr><td><p><strong>Weight</strong></p></td><td><p><strong>One dose is</strong></p></td></tr><tr><td><p>between 15 and 30 kilograms</p></td><td><p>375 milligram Darista + 50 milligram ritonavir twice a day</p></td></tr><tr><td><p>between 30 and 40 kilograms</p></td><td><p>450 milligram Darista + 60 milligram ritonavir twice a day</p></td></tr><tr><td><p>More than 40kilogram*</p></td><td><p>600 milligram Darista + 100 milligram ritonavir twice a day</p></td></tr></tbody></table><p>&nbsp;</p><p>*For children aged 12 or more and weighing at least 40 kilograms, your child&rsquo;s doctor will determine if Darista 800 milligram once daily dosing may be used. This cannot be administered with these 600 milligram tablets. Other strengths of Darista are available.</p><p>&nbsp;</p><p>Once daily dosing</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Weight</strong></p></td><td><p><strong>One DARISTA dose is</strong></p></td><td><p><strong>One ritonavir</strong><sup>a</sup><strong> dose is</strong></p></td></tr><tr><td><p>between 15 and 30 kilograms</p></td><td><p>600 milligram</p></td><td><p>100 milligram</p></td></tr><tr><td><p>between 30 and 40 kilograms</p></td><td><p>675 milligram</p></td><td><p>100 milligram</p></td></tr><tr><td><p>More than 40 kilogram</p></td><td><p>800 milligram</p></td><td><p>100 milligram</p></td></tr></tbody></table><p>&nbsp;</p><p>a - ritonavir oral solution: 80 milligram per millilitre</p><p>&nbsp;</p><p><strong>Instructions for children </strong></p><p>- The child must take Darista always together with ritonavir. Darista cannot work properly without ritonavir.</p><p>- The child must take the appropriate doses of Darista and ritonavir two times per day or once a day. If prescribed Darista twice daily the child must take one dose in the morning, and one dose in the evening. Your child&rsquo;s doctor will determine the appropriate dosing regimen for your child.</p><p>- The child must take Darista with food. Darista cannot work properly without food. The type of food is not important.</p><p>- The child must swallow the tablets with a drink such as water or milk.</p><p><strong>&nbsp;</strong></p><p><strong>Removing the child resistant cap </strong></p><p>The plastic bottle comes with a child resistant cap and must be opened as follows:</p><p>- Push the plastic screw cap down while turning it counter clockwise.</p><p>- Remove the unscrewed cap.</p><p>&nbsp;</p><p><strong>If you take more Darista </strong><strong>than you should </strong></p><p>Contact your doctor, pharmacist or nurse immediately.</p><p>&nbsp;</p><p><strong>If you forget to take Darista </strong><strong> </strong></p><p><strong>400 mg: </strong></p><p>If you notice <strong>within 12 hours</strong>, you must take the tablets immediately. Always take with cobicistat or ritonavir and food. If you notice <strong>after 12 hours</strong>, then skip the intake and take the next doses as usual. Do not take a double dose to make up for a forgotten dose</p><p><strong>600 mg:</strong></p><p>If you notice <strong>within 6 hours</strong>, you must take your missed dose immediately. Always take with ritonavir and food. If you notice <strong>after 6 hours</strong>, then skip the intake and take the next doses as usual. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>Do not stop taking Darista </strong><strong>without talking to your doctor first </strong></p><p>Anti-HIV medicines may make you feel better. Even when you feel better, do not stop taking Darista . Talk to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor if you develop any of the following side effects. </strong></p><p>Liver problems that may occasionally be severe have been reported. Your doctor should do blood tests before you start Darista . If you have chronic hepatitis B or C infection, your doctor should check your blood tests more often because you have an increased chance of developing liver problems. Talk to your doctor about the signs and symptoms of liver problems. These may include yellowing of your skin or whites of your eyes, dark (tea coloured) urine, pale coloured stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching, or pain and discomfort on your right side below your ribs.</p><p>Skin rash (more often when used in combination with raltegravir), itching. The rash is usually mild to moderate. A skin rash might also be a symptom of a rare severe situation. It is therefore important to talk to your doctor if you develop a rash. Your doctor will advise you how to deal with your symptoms or whether Darista must be stopped.</p><p>&nbsp;</p><p>Other severe side effects were diabetes (common) and inflammation of the pancreas (uncommon).</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&nbsp;&nbsp; - diarrhoea.</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&nbsp;&nbsp; - vomiting, nausea, abdominal pain or distension, dyspepsia, flatulence</p><p>&nbsp; - headache<em>, </em>tiredness, dizziness, drowsiness, numbness, tingling or pain in hands or feet, loss</p><p>&nbsp;&nbsp;&nbsp; of strength, difficulty falling asleep.</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>- chest pain, changes in electrocardiogram, rapid heart beating</p><p>- decreased or abnormal skin sensibility, pins and needles, attention disturbance, loss of memory,&nbsp; problems with your balance</p><p>- difficulty breathing, cough, nosebleed, throat irritation</p><p>- inflammation of the stomach or mouth, heartburn, retching, dry mouth, discomfort of</p><p>the abdomen, constipation, belching</p><p>- kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night</p><p>- urticaria, severe swelling of the skin and other tissues (most often the lips or the eyes), eczema, excessive sweating, night sweats, hair loss, acne, scaly skin, colouration of nails</p><p>- muscle pain, muscle cramps or weakness, pain in extremity, osteoporosis</p><p>- slowing down of the thyroid gland function. This can be seen in a blood test.</p><p>- high blood pressure, flushing</p><p>- red or dry eyes</p><p>- fever, swelling of lower limbs due to fluids, malaise, irritability, pain</p><p>- symptoms of infection, herpes simplex</p><p>- erectile dysfunction, enlargement of breasts</p><p>- sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>- a reaction called DRESS [severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung]</p><p>- Heart attack, slow heart beating, palpitations</p><p>- Visual disturbance</p><p>- Chills, feeling abnormal</p><p>- a feeling of confusion or disorientation, altered mood, restlessness</p><p>- fainting, epileptic fits, changes or loss of taste</p><p>- Mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue</p><p>- running nose</p><p>- Skin lesions, dry skin</p><p>- Stiffness of muscles or joints, joint pain with or without inflammation</p><p>- Changes in some values of your blood cells or chemistry. These can be seen in the results of blood and/or urine tests. Your doctor will explain these to you. Examples are: increase in some white blood cells.</p><p>Some side effects are typical for anti-HIV medicines in the same family as DARISTA. These are:</p><p>- muscle pain, tenderness or weakness. On rare occasions, these muscle disorders have been serious.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Darunavir.</p><p>Each film-coated tablet tablet contains 400 mg or 600 mg Darunavir.</p><p>&nbsp;</p><p>The other ingredients are:</p><p><em>Tablet core</em>: Cellulose, Microcrystalline, Hydroxypropylcellulose, Crospovidone, Silica colloidal anhydrous, Magnesium stearate.</p><p><em>&nbsp;</em></p><p><em>Tablet coating:</em></p><p>400 mg &amp; 600 mg: Polyvinyl alcohol, Titanium dioxide, Macrogol, Talc, Sunset yellow FCF.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Darista 400: 
Light orange colored, oval shaped, biconvex, film coated tablets debossed with ‘D’ on one side and ‘400’ on another side.
Darista 600: 
Orange colored, oval shaped, biconvex, film coated tablets debossed with ‘D’ on one side and ‘600’ on another side.

Darista 400 mg & 600 mg tablets are supplied in 60’s count HDPE Container.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer </strong></p><p>Aurobindo Pharma Limited, Unit-X,</p><p>Plot No.l6, APIIC, Multi Products SEZ,</p><p>Menakuru Village, Naidupeta MandaL</p><p>S.P.S.R. Nellore District,</p><p>Andhra Pradesh, India.</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder </strong></p><p>Aurobindo Pharma Saudi Arabia Limited,</p><p>Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;ما هو داريستا؟</strong></p><p dir="RTL">يحتوي داريستا على المادة الفعالة دارونافير. وداريستا هو دواء مضاد للفيروسات الرجعية يستخدم لعلاج عدوى فيروس نقص المناعة البشري (HIV). وينتمي لمجموعة من الأدوية تسمى مثبطات البروتياز. يعمل داريستا عن طريق خفض كمية فيروس نقص المناعة البشري في جسدك. سيحسن ذلك من جهازك المناعي، ويخفض خطر تطور أمراض مرتبطة بعدوى فيروس نقص المناعة البشري.</p><p dir="RTL"><strong>فيما يستخدم؟</strong></p><p dir="RTL">يستخدم داريستا 600 لعلاج البالغين والأطفال من سن 3 سنوات وأكثر بشرط ألا ينقص وزن جسدهم عن 15 كجم، والمصابون بفيروس نقص المناعة البشري مع تلقيهم قبلًا لأدوية أخرى مضادة للفيروسات الرجعية.</p><p dir="RTL">يستخدم داريستا 400 لعلاج البالغين والأطفال من سن 3 سنوات وأكثر بشرط ألا ينقص وزن جسدهم عن 40 كجم، والمصابون بفيروس نقص المناعة البشري،&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يتلقوا أدوية مضادة للفيروسات الرجعية من قبل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع بعض المرضى الذين تلقوا بعض الأدوية المضادة للفيروسات الرجعية من قبل (سيحدد طبيبك ذلك).</p><p>&nbsp;</p><p dir="RTL">&nbsp;يجب أخذ دارونافير بالتزامن مع جرعة صغيرة من كوبيسيستات أو ريتونافير، بجانب الأدوية الأخرى المضادة لفيروس نقص المناعة البشري. سيحدد طبيبك المجموعة الدوائية المناسبة الأفضل لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ داريستا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> تجاه دارونافير أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)، أو تجاه كوبيسيستات أو ريتونافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>مشاكل كبدية حادة</strong>. واسأل طبيبك إن لم تكن متأكدًا من حدة مرضك الكبدي، فقد تحتاج لبعض الاختبارات الإضافية.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;لا تأخذ داريستا مع أي من الأدوية التالية</strong></p><p dir="RTL">&nbsp;إذا كنت تأخذ أي من التالي، اسأل طبيبك حول التغيير لدواء آخر.</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الدواء</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>غرض الدواء</strong></p></td></tr><tr><td><p dir="RTL"><em>أفانافيل</em></p></td><td><p dir="RTL">لعلاج خلل الانتصاب.</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;أستيميزول</em> أو <em>تيرفينادين</em></p></td><td><p dir="RTL">لعلاج أعراض الحساسية</p></td></tr><tr><td><p dir="RTL"><em>تريازولام</em> و<em>الميتازولام الفموي</em> (يؤخذ عن طريق الفم)</p></td><td><p dir="RTL">للمساعدة في النوم و/أو إزالة القلق</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;سيسابريد</em></p></td><td><p dir="RTL">&nbsp;لعلاج بعض حالات المعدة</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;كولشيسين</em> (إذا كانت لديك مشاكل كلوية و/أو كبدية)</p></td><td><p dir="RTL">&nbsp;لعلاج النقرس أو حمى البحر المتوسط العائلية</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;لوراسيدون</em> أو <em>بيموزايد</em> أو <em>كيتيابين</em> أو <em>سيرتيندول</em></p></td><td><p dir="RTL">&nbsp;لعلاج الحالات النفسية</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;قلويدات الإرجوت</em> مثل <em>إيرجوتامين</em> و<em>ثنائي هيدرو إيرجوتامين</em> و<em>إيرجوميترين</em> و<em>ميثيل إيرجونوفين</em></p></td><td><p dir="RTL">&nbsp;لعلاج الصداع النصفي</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;أميودارون، بيبريديل، درونيدارون، كينيدين، رانولازين</em></p></td><td><p dir="RTL">&nbsp;لعلاج بعض الاضطرابات القلبية مثل نبض القلب غير الطبيعي</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;لوفاستاتين وسيمفاستاتين ولوميتابيد</em></p></td><td><p dir="RTL">&nbsp;لخفض مستويات الكوليستيرول</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;ريفامبيسين</em></p></td><td><p dir="RTL">&nbsp;لعلاج بعض العدوات مثل السل</p></td></tr><tr><td><p dir="RTL">&nbsp;مجموعة المنتجات <em>لوبينافير/ريتونافير</em></p></td><td><p dir="RTL">&nbsp;ينتمي هذا الدواء المضاد لفيروس نقص المناعة البشري لنفس مجموعة داريستا</p></td></tr><tr><td><p dir="RTL"><em>إيلباسفير/جرازوبريفير</em></p></td><td><p dir="RTL">&nbsp;لعلاج عدوى الالتهاب الكبدي C</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;ألفوزوسين</em></p></td><td><p dir="RTL">&nbsp;لعلاج تضخم البروستاتا</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;سيلدينافيل</em></p></td><td><p dir="RTL">&nbsp;لعلاج ارتفاع ضغط الدم بالدورة الدموية الرئوية</p></td></tr><tr><td><p dir="RTL"><em>&nbsp;دابيجاترون، تيكاجليلور</em></p></td><td><p dir="RTL">&nbsp;للمساعدة في منع تكتل الصفيحات عند علاج المرضى الذين لديهم تاريخ إصابة بالأزمات القلبية</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&nbsp;لا تأخذ داريستا بالتزامن مع المنتجات التي تحتوي على عشبة القديس جون<em>Hypericum perforatum)</em>).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول داريستا.</p><p dir="RTL">&nbsp;داريستا ليس علاجًا لعدوى فيروس نقص المناعة البشري. فما زلت قابلًا للإصابة بفيروس نقص المناعة البشري أثناء أخذك لهذا الدواء، بالرغم من انخفاض الخطر مع العلاج الفعال المضاد للفيروسات الرجعية. تناقش مع طبيبك حول الاحتياطات اللازمة لتجنب نقل العدوي لأشخاص آخرين.</p><p dir="RTL">&nbsp;قد يظل الأشخاص الذين يأخذون داريستا معرضين للإصابة بالعدوات أو الأمراض الأخرى المرتبطة بعدوى فيروس نقص المناعة البشري. يجب أن تبقى على تواصل مع طبيبك.</p><p dir="RTL">&nbsp;قد يُصاب الاشخاص الذين يأخذون داريستا بطفح جلدي. ونادرًا ما يصبح هذا الطفح خطيرًا أو مهددًا للحياة. من فضلك تواصل مع طبيبك متى أُصبت بطفح.</p><p dir="RTL">&nbsp;قد يتواجد طفح (عادة ما يكون بسيط إلى متوسط) لدي المرضى الذين يأخذون داريستا ورالتيجرافير (لعدوى فيروس نقص المناعة البشري) بصورة أكثر شيوعًا من المرضى الذين يأخذون أي من الدواءين بشكل منفرد.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;أعلم طبيبك بحالتك <u>قبل</u> و<u>أثناء</u> العلاج</strong></p><p dir="RTL">&nbsp;تأكد من تحققك من النقاط التالية، وأعلم طبيبك إذا انطبق أي من التالي عليك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك إن كانت لديك <strong>مشاكل كبدية</strong> من قبل، متضمنًا عدوى الالتهاب الكبدي B وC. قد يقيم طبيبك مدى حدة مرضك الكبدي قبل أن يقرر إمكانية أخذك داريستا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك إن كنت مصابًا <strong>بالسكري</strong>. فقد يُزيد داريستا مستويات السكر في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك على الفور إن لاحظت أي <strong>أعراض للعدوي</strong> (على سبيل المثال، تضخم العقد الليمفاوية والحمى). فقد تظهر علامات وأعراض الالتهاب من العدوات السابقة لدي بعض المرضى المصابون بعدوى متقدمة لفيروس نقص المناعة البشري، ولديهم تاريخ من الإصابة بالعدوات الانتهازية، وذلك بمجرد بدء العلاج المضاد لفيروس نقص المناعة البشري.&nbsp; ويُعتقد أن هذه الأعراض تكون ناتجة عن تحسن الاستجابة المناعية للجسم، مما يسمح للجسم بمقاومة العدوات التي قد تتواجد بعد بدء العلاج المضاد لفيروس نقص المناعة البشري مباشرة. ويُعتقد أيضًا أن هذه الأعراض تكون ناتجة عن تحسن الاستجابة المناعية للجسم، مما يسمح للجسم بمقاومة العدوات التي ربما كانت متواجدة بدون أعراض واضحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالإضافة إلى العدوات الانتهازية، قد تتواجد اضطرابات المناعة الذاتية أيضًا (حالة تحدث عند مهاجمة الجهاز المناعي لأنسجة الجسم السليمة) بعد البدء في أخذ أدوية لعلاج عدوى فيروس نقص المناعة البشرية. وقد تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج. إذا لاحظت أي أعراض للعدوى أو أي أعراض أخرى مثل ضعف العضلات أو ضعف يبدأ باليدين والقدمين ويزحف تجاه جذع الجسم أو خفقان أو ارتجاف أو فرط نشاط، من فضلك أعلم طبيبك على الفور لطلب العلاج اللازم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك إن كنت مصابًا <strong>بسيولة الدم</strong>. فقد يُزيد داريستا من خطر حدوث نزف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك إن كانت لديك <strong>حساسية تجاه السلفوناميدات </strong>(على سبيل المثال، تُستخدم لعلاج بعض العدوات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلم طبيبك أن لاحظت أي <strong>مشاكل عضلية هيكلية</strong>. فقد يُصاب بعض المرضى الذين يأخذون مجموعة علاجية مضادة للفيروسات بمرض عظمي يُسمى النخر العظمي (موت النسيج العظمي، والذي يسببه عدم وصول الدم للعظام). وقد يكون طول مدة العلاج بالمجموعة المضادة للفيروسات، واستخدام الستيرويدات القشرية، وتناول الكحول، والتثبيط المناعي الحاد، وارتفاع معامل كتلة الجسم جزءًا من بعض عوامل الخطر المتسببة في ظهور هذا المرض.&nbsp; علامات النخر العظمي هي تيبس المفاصل والوجع والألم (وخاصة في الورك والركبة والكتف) وصعوبة السير. عند معاناتك من أي من هذه الإعراض، يجب عليك إخبار طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;كبار السن</strong></p><p dir="RTL">&nbsp;اُستخدم داريستا فقط بعدد قليل من المرضى بسن 65 عامًا أو أكبر. فإذا كنت تنتمي لهذه المجموعة العمرية، من فضلك تناقش مع طبيبك حول إمكانية استعمال داريستا.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;يُحظر استعمال داريستا مع الأطفال الأقل من 3 سنوات، أو الذين وزنهم أقل من 15 كيلوجرام.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأدوية الأخرى وداريستا</strong></p><p dir="RTL">&nbsp;أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى،</p><p dir="RTL">&nbsp;توجد بعض الأدوية التي <strong>لا يمكن أخذها</strong> مع داريستا. وهي مذكورة أعلاه تحت عنوان &quot;لا تأخذ داريستا مع أي من الأدوية التالية:&quot;</p><p dir="RTL">&nbsp;في معظم الحالات، لا يمكن أخذ داريستا مع الأدوية المضادة لفيروس نقص المناعة البشري التي تنتمي لفئة أخرى (على سبيل المثال، مثبطات إنزيم نسخ النيوكليوسايد العكسي (NRTIs)، مثبطات إنزيم النسخ العكسي لغير النيوكليوسيدات (NNRTIs)، مضادات مستقبلات كيموكين من النوع الخامس (CCR5)، مثبطات الاندماج (FIs)). لم يُختبر داريستا مع كوبيسيستات أو ريتونافير تجاه جميع مثبطات البروتياز (PIs)، ولا يجب استخدامه مع مثبطات بروتياز فيروس نقص المناعة البشري الأخرى. في بعض الحالات، قد تكون هناك حاجة لتغيير جرعات بعض الأدوية، ولذلك أعلم طبيبك دائمًا إن كنت تأخذ أدوية أخرى مضادة لفيروس نقص المناعة البشري، واتبع تعليمات طبيبك بدقة حول أي من الأدوية التي يمكن أخذها مع داريستا.</p><p>&nbsp;</p><p dir="RTL">&nbsp;قد تنخفض تأثيرات داريستا إذا أخذت أي من المنتجات التالية. أعلم طبيبك إن كنت تأخذ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>فينوباربيتول، فينايتوين</em> (لمنع النوبات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ديكساميثازون</em> (ستيرويد قشري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>إيفافيرينز</em> (عدوى فيروس نقص المناعة البشري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>بوسيبريفير</em> (عدوى الالتهاب الكبدي C)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ريفامبيسين، ريفابيوتين</em> (أدوية تستخدم لعلاج بعض العدوات مثل السل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ساكينافير</em> (عدوى فيروس نقص المناعة البشري)</p><p>&nbsp;</p><p dir="RTL">&nbsp;قد تتأثر تأثيرات بعض الأدوية إذا أخذت داريستا. أعلم طبيبك إن كنت تأخذ:</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>أملوديبين، ديلتيازيم، ديسوبيراميد، كارفيديلول، فيلوديبين، فليكينيد، ليدوكين، ميتوبرولول، ميكسيليتين، نايفديبين، نيكارديبين، بروبافينون، تايمولول، فيراباميل (لأمراض القلب)، فقد تزداد الآثار العلاجية أو الآثار الجانبية لهذه الأدوية.</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أبيكسابان، إيدوكسابان، ريفاروكسابان، وارفارين</em> (لخفض تخثر الدم)، فقد تتغير آثارهم العلاجية أو الجانبية، وقد يحتاج طبيبك لفحص دمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل المعتمدة على إيستروجين وعلاج الاستبدال الهرموني. فقد يُخفض داريستا من فعاليتهم. يوصى بطرق بديلة تعتمد على موانع حمل غير هرمونية عند الاستخدام في تحديد النسل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>إيثينيل إستراديول/دروسبيرينون.</em> قد يُزيد داريستا من خطر ارتفاع مستويات البوتاسيوم عن طريق دروسبيرينون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أتورفاستاتين، برافاستاتين، روسوفاستاتين</em> (لخفض مستويات الكوليستيرول). فقد يزداد خطر الإصابة بتلف العضلات. سيحدد طبيبك أي من أنظمة خفض الكوليستيرول يكون ملائمًا لحالتك الخاصة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>كلاريثروميسين</em> (مضاد حيوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>سيكلوسبورين، إيفيروليموس، تاكروليموس، سايروليموس</em> (لتثبيط جهازك المناعي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا لاحتمالية زيادة الآثار العلاجية أو الجانبية لهذه الأدوية، فقد يحتاج طبيبك لإجراء بعض الاختبارات الإضافية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الستيرويدات القشرية التي تحتوي على بيتاميثازون، بوديسونيد، فلوتيكاسون، موميتاسون، بريدنيسون، تريامسينولون.</em> تُستخدم هذه الأدوية لعلاج الحساسيات، والربو، وأمراض التهاب الأمعاء، وحالات التهاب العينين، وحالات التهاب المفاصل والعضلات الأخرى. في حالة عدم إمكانية استخدام دواء بديل، يجب أن يُستخدم فقط بعد التقييم الطبي، وتحت إشراف الطبيب للتحقق من الآثار الجانبية للستيرويدات القشرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>بابرينورفاين/نالوكسون </em>(أدوية لعلاج التعلق بالمواد الأفيونية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>سالميتيرول</em> (دواء لعلاج الربو)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أرتيميثير/ليوميفانترين</em> (مجموعة أدوية لعلاج الملاريا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>داساتينيب، إيفيروليموس، نايلوتينيب، فينبلاستين، فينكريستين</em> (لعلاج السرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>سيلدينافيل، تادالافيل، فاردينافيل</em> (لعلاج خلل الانتصاب أو لعلاج اضطراب بالقلب والرئتين يُدعى ارتفاع ضغط دم الشرايين الرئوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>جليكابريفير/بايبرينتاسفير، سيميبريفير</em> لعلاج عدوى الالتهاب الكبدي C))</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>فينتانيل، أوكسيكودون، ترامادول</em> (لعلاج الألم)</p><p dir="RTL">&nbsp;قد يلزم تغيير جرعة أدوية أخرى لتأثر آثارهم الدوائية والجانبية أو لتأثر آثار داريستا الدوائية والجانبية عند استعمالهم معًا.</p><p dir="RTL">&nbsp;أعلم طبيبك إن كنت تأخذ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ألفينتانيل</em> (مسكن للألم قوي قصير المفعول يؤخذ عن طريق الحقن، ويُستخدم بالعمليات الجراحية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ديجوكسين</em> (لعلاج بعض الاضطرابات القلبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>كلاريثروميسين</em> (مضاد حيوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>إيتراكونازول، إيسافوكونازول، فلوكونازول، بوساكونازول، كلوتريمازول</em> (لعلاج العدوات الفطرية). ويجب أخذ فوريكونازول فقط بعد التقييم الطبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ريفابيوتين</em> (مضاد للعدوات البكتيرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>سيلدينافيل، فاردينافيل، تادالافيل</em> (لعلاج خلل الانتصاب أو ارتفاع ضغط الدم في الدورة الدموية الرئوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أميتريبتايلين، ديسيبرامين، إيميبرامين، نورتريبتيلين، باروكسيتين، سيرترالين، ترازودون</em> (لعلاج الاكتئاب والقلق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>مارافيروك</em> (لعلاج عدوى فيروس نقص المناعة البشري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ميثادون</em> (لعلاج إدمان الأفيون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>كاربامازيبين، كلونازيبام</em> (لمنع حدوث النوبات أو لعلاج بعض أنواع الآلام العصبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>كولشيسين</em> (لعلاج النقرس أو حمى البحر المتوسط العائلية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>بوسينتان</em> (لعلاج ارتفاع ضغط الدم بالدورة الدموية الرئوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>بوسبيرون، كلورازيبات، ديازيبام، إيستازولام، فلورازيبام، ميتازولام عندما يُستعمل عن طريق الحقن، زولديبيم</em> (عوامل مخدرة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>بيرفينازين، ريسبيريدون، ثيوريدازين</em> (لعلاج الحالات النفسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ميتفورمين</em> (لعلاج السكري من النوع الثاني)</p><p>&nbsp;</p><p dir="RTL">هذه <strong>ليست</strong> قائمة كاملة للأدوية. ويجب أن تُعلم مقدم رعايتك العلاجية <strong><em>بجميع</em></strong> الأدوية التي تأخذها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>داريستا مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;انظر القسم 3 &quot;كيفية أخذ داريستا&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">أعلمي طبيبك على الفور إن كنتي حاملًا، أو تخططين للحمل، أو إن كنتي ترضعين. وذلك لأن الأمهات اللاتي ترضعن لا يجب عليهن أخذ داريستا مع ريتونافير مالم يرشدهم الطبيب لذلك بشكل خاص.<u> يُحظر على الأمهات المرضعات أخذ داريستا مع كوبيسيستات.</u></p><p dir="RTL">يوصى بعدم قيام النساء المصابات بفيروس نقص المناعة البشري بإرضاع أطفالهم، وذلك لإمكانية إصابة طفلك بفيروس نقص المناعة البشرية عن طريق حليب الثدي، ولعدم معرفة آثار الدواء على طفلك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;لا تقم بإدارة الآلات أو بالقيادة إذا شعرت بدوخة بعد أخذ داريستا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;يحتوي داريستا على إف سي إف أصفر بلون الغروب (</strong><strong>E110)</strong>، والذي قد يسبب ردود فعل تحسسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;خذ هذا الدواء دائمًا كما أخبرك طبيبك أو الصيدلي أو الممرضة بالضبط، وتحقق من طبيبك أو الصيدلي أو الممرضة إن لم تكن متأكدًا.</p><p dir="RTL">&nbsp;وحتى إن شعرت بالتحسن، لا تتوقف عن أخذ داريستا وريتونافير دون التحدث إلى طبيبك.</p><p dir="RTL">&nbsp;بعد بدء العلاج، لا يجب تغيير الجرعة أو شكل الجرعة، أو لا يجب إيقاف العلاج بدون توجيهات الطبيب.</p><p>&nbsp;</p><p dir="RTL">تُستخدم أقراص داريستا 400 مجم فقط لإنشاء نظام جرعة 800 مجم مرة واحدة يوميًا.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة للبالغين الذين لم يأخذوا أدوية مضادة للفيروسات الرجعية من قبل (سيحدد طبيبك ذلك)</strong></p><p dir="RTL">&nbsp;ستحتاج إلى جرعة مختلفة من داريستا لا يمكن تطبيقها باستعمال أقراص 600 مجم. توجد قوي أخرى متاحة لداريستا.</p><p dir="RTL">الجرعة المعتادة من داريستا هي 800 مجم (قرصين يحتويان على 400 مجم من داريستا، أو قرص واحد يحتوي على 800 مجم من داريستا) مرة واحدة يوميًا.</p><p dir="RTL">يجب أخذ داريستا كل يوم، ويؤخذ دائمًا مع كوبيسيستات 150 مجم أو ريتونافير 100 مجم بجانب الطعام. حيث أن داريستا لا يعمل جيدًا بدون كوبيسيستات أو ريتونافير والطعام. يجب أن تتناول الطعام أو المقبلات خلال 30 دقيقة قبل أخذ داريستا وكوبيسيستات أو ريتونافير، ولا يهم نوع الطعام. وحتى إن شعرت بالتحسن، لا تتوقف عن أخذ داريستا وكوبيسيستات أو ريتونافير دون التحدث إلى طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;التعليمات للبالغين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ قرصين 400 مجم في نفس الوقت مرة واحدة يوميًا كل يوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ داريستا دائمًا مع كوبيسيستات 150 مجم أو ريتونافير 100 مجم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ داريستا مع الطعام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص بمشروب مثل الماء أو الحليب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ أدوية فيروس نقص المناعة البشري الأخرى التي تستعمل مع داريستا، وكوبيسيستات أو ريتونافير كما يوصي طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الجرعة للبالغين الذين أخذوا أدوية مضادة للفيروسات الرجعية من قبل (سيحدد طبيبك ذلك)</strong></p><p dir="RTL">&nbsp;تكون الجرعة واحدًا من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 600 مجم داريستا (قرص واحد يحتوي على 600 مجم من داريستا) مع ريتونافير 100 مجم مرتين يوميًا.</p><p dir="RTL">&nbsp;أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 800 مجم داريستا (قرصان يحتويان على 400 مجم من داريستا أو قرص واحد يحتوي على 800 مجم من داريستا) مع ريتونافير 100 مجم مرة واحدة يوميًا. تُستخدم أقراص داريستا 400 مجم و800 مجم فقط لإنشاء نظام جرعة 800 مجم مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;من فضلك تناقش مع طبيبك حول الجرعة الأمثل لك.</p><p>&nbsp;</p><p dir="RTL"><strong>التعليمات للبالغين</strong></p><p dir="RTL">&nbsp;خذ داريستا دائمًا مع ريتونافير. حيث أن داريستا لا يعمل جيدًا بدون ريتونافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الصباح، خذ قرص واحد من داريستا 600 مجم مع 100 مجم من ريتونافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المساء، خذ قرص واحد من داريستا 600 مجم مع 100 مجم من ريتونافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ داريستا مع الطعام. حيث أن داريستا لا يعمل جيدًا بدون الطعام. ولا يهم نوع الطعام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص بمشروب مثل الماء أو الحليب.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة للأطفال من سن 3 سنوات وأكثر ذوي الوزن الأعلى من 15 كجم، والذين لم يأخذوا أدوية مضادة للفيروسات الرجعية من قبل (سيحدد طبيب طفلك ذلك)</strong></p><p>&nbsp;</p><p dir="RTL">&nbsp;سيتخذ طبيبك الإجراء الصحيح عند تحديد الجرعة اليومية بناءً على وزن الطفل (انظر الجدول أدناه). ولا يجب أن تتجاوز هذه الجرعة تلك الجرعة الموصي بها للبالغين وهي 800 مجم من داريستا مع 100 مجم ريتونافير مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;سيعلمك طبيبك بالجرعة التي يجب أن يأخذها طفلك من أقراص داريستا ومن ريتونافير (كبسولات أو أقراص أو محلول)</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>الوزن</strong></p></td><td><p dir="RTL"><strong>الجرعة الواحدة من داريستا هي</strong></p></td><td><p dir="RTL"><strong>الجرعة الواحدة من ريتونافير<sup>أ</sup> هي</strong></p></td></tr><tr><td><p dir="RTL">ما بين 15 إلى 30 كيلوجرام</p></td><td><p dir="RTL">600 ميللي جرام</p></td><td><p dir="RTL">100 ميللي جرام</p></td></tr><tr><td><p dir="RTL">ما بين 30 إلى 40 كيلوجرام</p></td><td><p dir="RTL">675 ميللي جرام</p></td><td><p dir="RTL">100 ميللي جرام</p></td></tr><tr><td><p dir="RTL">أكثر من 40 كيلوجرام</p></td><td><p dir="RTL">800 ميللي جرام</p></td><td><p dir="RTL">100 مجم</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">أ - محلول ريتونافير فموي: 80 ميللي جرام لكل ميللي لتر</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة للأطفال من سن 3 سنوات وأكثر ذوي الوزن الأعلى من 15 كجم، والذين أخذوا أدوية مضادة للفيروسات الرجعية من قبل (سيحدد طبيب طفلك ذلك)</strong></p><p dir="RTL">سيتخذ طبيبك الإجراء الصحيح عند تحديد الجرعة اليومية بناءً على وزن الطفل (انظر الجدول أدناه). سيحدد طبيبك ما إذا كان من المناسب أن يأخذ طفلك جرعة واحدة يوميًا أو جرعتين يوميًا. ولا يجب أن تتجاوز هذه الجرعة تلك الجرعة الموصي بها للبالغين وهي 600 مجم من داريستا مع 100 مجم ريتونافير مرتين يوميًا، أو 800 مجم داريستا مع 100 مجم ريتونافير مرة واحدة يوميًا. سيعلمك طبيبك بالجرعة التي يجب أن يأخذها طفلك من أقراص داريستا ومن ريتونافير (كبسولات أو أقراص أو محلول). وتوجد أقراص ذات قوة أقل لتحديد نظام الجرعات الأمثل.</p><p>&nbsp;</p><p dir="RTL">&nbsp;نظام الجرعات مرتين يوميًا</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p dir="RTL">الوزن</p></td><td><p dir="RTL">الجرعة الواحدة هي</p></td></tr><tr><td><p dir="RTL">ما بين 15 إلى 30 كيلوجرام</p></td><td><p dir="RTL">375 ميللي جرام داريستا + 50 ميللي جرام ريتونافير مرتين يوميًا</p></td></tr><tr><td><p dir="RTL">ما بين 30 إلى 40 كيلوجرام</p></td><td><p dir="RTL">450 ميللي جرام داريستا + 60 ميللي جرام ريتونافير مرتين يوميًا</p></td></tr><tr><td><p dir="RTL">أكثر من 40 كيلوجرام*</p></td><td><p dir="RTL">600 ميللي جرام داريستا + 100 ميللي جرام ريتونافير مرتين يوميًا</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">*للأطفال من عمر 12 عام وأكثر والذين وزنهم أعلى من 40 كجم، وسيحدد طبيبك إمكانية استخدام جرعة داريستا 800 مجم مرة واحدة يوميًا. ولا يجب أخذها مع أقراص 600 مجم. توجد قوي أخرى متاحة لداريستا.</p><p>&nbsp;</p><p dir="RTL">&nbsp;نظام الجرعات مرة واحدة يوميًا</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">الوزن</p></td><td><p dir="RTL">الجرعة الواحدة من داريستا هي</p></td><td><p dir="RTL"><strong>الجرعة الواحدة من ريتونافير<sup>أ</sup> هي</strong></p></td></tr><tr><td><p dir="RTL">ما بين 15 إلى 30 كيلوجرام</p></td><td><p dir="RTL">600 ميللي جرام</p></td><td><p dir="RTL">100 ميللي جرام</p></td></tr><tr><td><p dir="RTL">ما بين 30 إلى 40 كيلوجرام</p></td><td><p dir="RTL">675 ميللي جرام</p></td><td><p dir="RTL">100 ميللي جرام</p></td></tr><tr><td><p dir="RTL">أكثر من 40 كيلوجرام</p></td><td><p dir="RTL">800 ميللي جرام</p></td><td><p dir="RTL">100 ميللي جرام</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">أ - محلول ريتونافير فموي: 80 ميللي جرام لكل ميللي لتر</p><p>&nbsp;</p><p dir="RTL"><strong>التعليمات للأطفال</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يأخذ الطفل دائمًا داريستا مع ريتونافير. حيث أن داريستا لا يعمل جيدًا بدون ريتونافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يأخذ الطفل الجرعة الصحيحة من داريستا وريتونافير مرتين يوميًا أو مرة واحدة يوميًا. وفي حالة وصف داريستا مرتين يوميًا، يجب أن يأخذ الطفل جرعة واحدة في الصباح وجرعة واحدة في المساء. سيحدد طبيبك نظام الجرعات المناسب لطفلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يأخذ الطفل دائمًا داريستا مع الطعام. حيث أن داريستا لا يعمل جيدًا بدون الطعام. ولا يهم نوع الطعام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على الطفل أن يبتلع الأقراص بمشروب مثل الماء أو الحليب.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;نزع الغطاء المقاوم لاستخدام الأطفال</strong></p><p dir="RTL">&nbsp;تأتي الزجاجة البلاستيكية بغطاء مقاوم لاستخدام الأطفال، ويجب فتحها كما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط على الغطاء البلاستيكي الحلزوني للأسفل مع إدارته عكس اتجاه عقارب الساعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الغطاء غير الملتف.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا اخذت داريستا أكثر مما يجب</strong></p><p dir="RTL">&nbsp;تواصل مع طبيبك أو الصيدلي أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;إذا نسيت تناول داريستا</strong></p><p dir="RTL"><strong>&nbsp;400 مجم:</strong></p><p dir="RTL">&nbsp;إذا لاحظت ذلك <strong>خلال 12 ساعة</strong>، يجب أن تأخذ الأقراص على الفور. ويجب أن تأخذها دائمًا مع كوبيسيستات أو ريتونافير مع وجود الطعام. إذا لاحظت ذلك <strong>بعد 12 ساعة</strong>، لا تأخذ تلك الجرعة وخذ الجرعات التي تليها وفقًا للمعتاد. لا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p dir="RTL"><strong>600 مجم</strong></p><p dir="RTL">إذا لاحظت ذلك <strong>خلال 6 ساعات</strong>، يجب أن تأخذ الأقراص على الفور. ويجب أن تأخذها دائمًا مع ريتونافير مع وجود الطعام. إذا لاحظت ذلك <strong>بعد 6 ساعات</strong>، لا تأخذ تلك الجرعة وخذ الجرعات التي تليها وفقًا للمعتاد. ولا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;لا تتوقف عن أخذ داريستا دون التحدث مع طبيبك أولًا.</strong></p><p dir="RTL">&nbsp;قد تجعلك الأدوية المضادة لفيروس نقص المناعة البشري تشعر بالتحسن. ولكن حتى إن شعرت بالتحسن، لا تتوقف عن أخذ داريستا. وتحدث مع طبيبك أولًا.</p><p dir="RTL">&nbsp;إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، اسأل طبيبك أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد تحدث زيادة في الوزن ومستويات الليبيدات والجلوكوز في الدم أثناء علاج فيروس نقص المناعة البشري. ويرتبط ذلك جزئيًا باسترداد الحالة الصحية والحياتية، وفي حالة الليبيدات في الدم، يرتبط أحيانًا بالأدوية المضادة لفيروس نقص المناعة البشري نفسها. سيختبر طبيبك تلك التغيرات.</p><p dir="RTL">مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>أعلم طبيبك إن أُصبت بأي من الآثار الجانبية التالية.</strong></p><p dir="RTL">الإبلاغ عن مشاكل كبدية قد تكون خطيرة أحيانًا. يجب حينئذ أن يجري طبيبك اختبارات للدم قبل بدء العلاج بداريستا. إذا كانت لديك عدوي مزمنة للالتهاب الكبدي B أو C، يجب أن تتحقق من اختبارات دمك بشكل أكبر، وذلك لزيادة احتمالية حدوث مشاكل بالكبد. تحدث مع طبيبك حول علامات وأعراض المشاكل الكبدية، والتي قد تشتمل على اصفرار الجلد أو ابيضاض العينين، أو بول قاتم (لون الشاي)، أو براز شاحب اللون (حركات معوية)، أو غثيان، أو قيء، أو فقدان شهية، أو ألم، أو وجع، أو ألم واضطراب بجانبك الأيمن تحت الضلوع.</p><p>&nbsp;</p><p dir="RTL">طفح جلدي (يحدث غالبًا عند الاستعمال مع رالتيجرافير)، حكة. وعادة ما يكون الطفح بسيط إلى متوسط. قد يكون الطفح الجلدي أيضًا علامة لحالة خطيرة نادرة، لذا من المهم أن تتحدث مع طبيبك إذا أُصبت بطفح. سيخبرك طبيبك بكيفية التعامل مع أعراضك، وما إذا كان يجب إيقاف داريستا.</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية الحادة الأخرى هي السكري (شائع) والتهاب البنكرياس (غير شائع).</p><p dir="RTL"><strong>&nbsp;آثار جانبية شائعة جدًا (قد تصيب أكثر من 1 لكل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;آثار جانبية شائعة (قد تصيب 1 لكل 10 أشخاص)</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp; قيء، غثيان، ألم أو انتفاخ بالبطن، عسر هضم، امتلاء البطن بالغازات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، إرهاق، دوخة، نعاس، تنميل، وخز أو ألم باليدين أو القدمين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان القوة، صعوبة النوم.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;آثار جانبية غير شائعة (قد تصيب 1 لكل 100 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر، تغيرات برسم القلب الكهربائي، سرعة نبض القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو شذوذ الإحساس بالجلد، شعور بالوخز، اضطراب الانتباه، فقدان الذاكرة، مشاكل بالاتزان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس، سعال، نزف الأنف، تهيج الحلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة أو الفم، حرقة المعدة، الرغبة في القيء، جفاف الفم، اضطراب البطن،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، تجشؤ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي، حصوات بالكلى، صعوبة إخراج البول، إخراج البول المتكرر أو الزائد، وعادة ما يكون بالليل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى، تورم حاد بالجلد والأنسجة الأخرى (غالبًا الشفتين أو العينين)، إكزيما، تعرق زائد، عرق ليلي، تساقط الشعر، بثور، تحرشف الجلد، تلون الأظافر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات، تشنجات أو ضعف بالعضلات، ألم شديد، هشاشة عظام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ وظائف الغدة الدرقية. ويمكن رؤية ذلك باختبارات الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، دفق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعين حمراء أو جافة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، تورم الأطراف السفلية نتيجة السوائل، توعك، تهيج، ألم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات العدوى، هربس بسيط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الانتصاب، كبر الثديين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالنوم، نعاس، قلق، أحلام غير طبيعية، نقص بالدافع الجنسي.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تصيب 1 لكل 1000 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل يُدعى الطفح الدوائي المصحوب بفرط الحمضات والأعراض الجهازية (DRESS)، وأعراضه هي طفح شديد قد تصاحبه حمى، إعياء، تورم الوجه أو الغدد الليمفاوية، زيادة الحمضات (نوع من خلايا الدم البيضاء)، آثار على الكبد أو الكلى أو الرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية، بطء نبض القلب، خفقان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بصرية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، شعور بالتوعك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالارتباك وعدم التوازن، تغير المزاج، عدم الراحة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، نوبات صرع، تغير أو فقدان لحاسة التذوق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح الفم، قيء دموي، التهاب الشفتين، جفاف الشفتين، تغلف اللسان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آفات الجلد، جفاف الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل أو العضلات، ألم المفاصل المصحوب بالتهاب أو بدونه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير ببعض قيم خلايا الدم أو كيمياء الدم. ويمكن رؤية ذلك بنتائج اختبارات الدم و/أو البول. سيوضح الطبيب ذلك لك. الأمثلة هي: زيادة ببعض خلايا الدم البيضاء.</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون نموذجية للأدوية المضادة لفيروس نقص المناعة البشري في نفس العائلة التي ينتمي لها داريستا، وهي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ترقق أو ضعف بالعضلات. وفي بعض الحالات النادرة، تصبح هذه الاضطرابات العضلية خطيرة.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;إذا حدث لك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة بهذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ هذا الدواء بعيدا عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العبوة والزجاجة بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يخزن في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. أسال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;المادة الفعالة هي دارونافير.</p><p dir="RTL">&nbsp;يحتوي كل قرص مغلف على 400 مجم أو 600 مجم من دارونافير.</p><p>&nbsp;</p><p dir="RTL">&nbsp;المكونات الأخرى هي:</p><p dir="RTL"><em>&nbsp;جسم القرص:</em> سيليولوز دقيق التبلور، هيدروكسي بروبيل سيليولوز، كروسبوفيدون، سيليكا غروية لا مائية، ستيرات ماغنسيوم.</p><p><em>&nbsp;</em></p><p dir="RTL"><em>غلاف القرص:</em></p><p dir="RTL">400 مجم و600 مجم:<strong> </strong>كحول البولي فينيل، ثاني أكسيد التيتانيوم، ماكروجول، تلك، إف سي إف أصفر بلون الغروب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><u>&nbsp;داريستا 400:</u></p><p>&nbsp;أقراص بيضاوية مغلفة ثنائية التحدب ذات لون برتقالي فاتح، ومنقوش على أحد جانبيها &quot;D&quot;، وعلى الجانب الآخر &quot;400&quot;.</p><p><u>داريستا 600:</u></p><p>&nbsp;أقراص بيضاوية مغلفة ثنائية التحدب ذات لون برتقالي، ومنقوش على أحد جانبيها &quot;D&quot;، وعلى الجانب الآخر &quot;600&quot;.</p><p>&nbsp;</p><p dir="RTL">تورد أقراص داريستا 400 مجم و600 مجم بأوعية من البولي إيثيلين عالي الكثافة تحتوي على 60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة</strong></p><p dir="RTL">أوروبيندو فارما المحدودة، الوحدة-X،</p><p dir="RTL">قطعة رقم 16، مؤسسة أندهرا براديش للبنية التحتية الصناعية، المنطقة الاقتصادية الخاصة،</p><p dir="RTL">قرية ميناكورو، مقاطعة نيدوبيتا</p><p dir="RTL">إس بي إس آر. حي نيلور،</p><p dir="RTL">أندهرا براديش، الهند.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">أوروبيندو فارما السعودية المحدودة،</p><p dir="RTL">جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Darista 400 (Darunavir Tablets 400 mg)
Darista 600 (Darunavir Tablets 600 mg)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Darunavir Tablets 400 mg:
Each film coated tablet contains Darunavir Propylene Glycolate equivalent to 400 mg of Darunavir.
Darunavir Tablets 600 mg:
Each film coated tablet contains Darunavir Propylene Glycolate equivalent to 600 mg of Darunavir.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                    Darunavir Tablets 400 mg:
Light orange colored, oval shaped, biconvex, film coated tablets debossed with ‘D’ on one side and ‘400’ on another side.
Darunavir Tablets 600 mg:
  Orange colored, oval shaped, biconvex, film coated tablets debossed with ‘D’ on one side 
   and ‘600’ on another side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.</p><p>Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.</p><p>Darunavir 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:</p><p>&bull; Antiretroviral therapy (ART)-na&iuml;ve.</p><p>&bull; ART-experienced with no Darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 106/l. In deciding to initiate treatment with Darunavir in such ART experienced patients, genotypic testing should guide the use of Darunavir.</p><p>600 mg tablet may be used to provide suitable dose regimens :</p><p>&bull; For the treatment of HIV-1 infection in antiretroviral treatment ART-experienced adult patients, including those that have been highly pre-treated.</p><p>&bull; For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. In deciding to initiate treatment with Darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing {when available} and treatment history should guide the use of Darunavir</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a health care provider experienced in the management of HIV infection. After therapy with Darunavir has been initiated, patients should be advised not to alter the dosage, dose form or discontinue therapy without discussing with their health care provider.</p><p>The interaction profile of Darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.</p><p>Darunavir may therefore have different contraindications and recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Darunavir must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products. The Summary of Product Characteristics of cobicistat or ritonavir as appropriate must therefore be consulted prior to initiation of therapy with Darunavir Cobicistat is not indicated for use in twice daily regimens or for use in the paediatric population.</p><p>Darunavir is also available as an oral suspension for use in patients who are unable to swallow Darunavir tablets (please refer to the Summary of Product Characteristics for Darunavir oral suspension).</p><p><em>ART-na&iuml;ve adult patients</em></p><p><em>&nbsp;</em></p><p>The recommended dose regimen is 800 mg once daily with cobicistat 150 mg once daily or ritonavir 100 mg once daily taken with food. Darunavir 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.</p><p>&nbsp;</p><p><em>ART-experienced adult patients</em></p><p><em>&nbsp;</em></p><p>The recommended dose regimens are as follows:</p><p>&bull; In ART-experienced patients with no Darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 106/l. a regimen of 800 mg once daily with cobicistat 150 mg once daily or ritonavir 100 mg once daily taken with food may be used. Darunavir 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.</p><p>&bull; In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. See the Summary of Product Characteristics for Darunavir 100 mg/ml oral suspension, 75 mg, 150 mg, 300 mg or 600 mg tablets.</p><p>* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</p><p>&nbsp;</p><p><em>ART-na&iuml;ve paediatric patients (3 to 17 years of age and weighing at least 40 k g)</em></p><p><em>&nbsp;</em></p><p>The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food. The dose of cobicistat to be used with Darunavir in children less than 18 years of age has not been established.</p><p>&nbsp;</p><p><em>ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 k g)</em></p><p><em>&nbsp;</em></p><p>The dose of cobicistat to be used with Darunavir in children less than 18 years of age has not been established.</p><p>The recommended dose regimens are as follows:</p><p>&bull; In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 10<sup>6</sup>/I a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used. Darunavir 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.</p><p>&bull; In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is described in the Summary of Product Characteristics for Darunavir 100 mg/ml oral suspension,75 mg, 150 mg, 300 mg and 600 mg tablets.</p><p>* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</p><p>&nbsp;</p><p><em>Advice on missed doses</em></p><p>If a once daily dose of Darunavir and/or cobicistat or ritonavir is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of Darunavir and cobicistat or ritonavir with food as soon as possible. If this is noticed later than 12 hours after the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.</p><p>This guidance is based on the half-life of Darunavir in the presence of cobicistat or ritonavir and the recommended dosing interval of approximately 24 hours.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>Elderly</u></em></p><p>Limited information is available in this population, and therefore, Darunavir should be used with caution in this age group.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Darunavir is metabolised by the hepatic system. No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, Darunavir should be used with caution in these patients. No pharmacokinetic data are available in patients with severe hepatic impairment. Severe hepatic impairment could result in an increase of Darunavir exposure and a worsening of its safety profile. Therefore, Darunavir must not be used in patients with severe hepatic impairment (Child-Pugh Class C).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required for Darunavir/ritonavir in patients with renal impairment. Cobicistat has not been studied in patients receiving dialysis, and, therefore, no recommendation can be made for the use of Darunavir/cobicistat in these patients.</p><p>Cobicistat inhibits the tubular secretion of creatinine and may cause modest increases in serum creatinine and modest declines in creatinine clearance. Hence, the use of creatinine clearance as an estimate of renal elimination capacity may be misleading. Cobicistat as a pharmacokinetic enhancer of Darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or adefovir dipovoxil.</p><p>For information on cobicistat, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Darunavir should not be used in paediatric patients below 3 years of age or less than 15 kg body weight.</p><p>&nbsp;</p><p><em>ART-na&iuml;ve paediatric patients (3 to 17 years of age and weighing at least 40 k g)</em></p><p><em>&nbsp;</em></p><p>The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.</p><p>&nbsp;</p><p><em>ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 k g)</em></p><p><em>&nbsp;</em></p><p>In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 106/l, a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used.</p><p>* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</p><p>For dosage recommendations in children, see the Summary of Product Characteristics for Darunavir 75 mg, 150 mg, 300 mg, 600 mg tablets and 100 mg/ml oral suspension.</p><p>&nbsp;</p><p>The dose of cobicistat to be used with Darunavir has not been established in this patient population.</p><p>&nbsp;</p><p><em>Pregnancy and postpartum</em></p><p>No dose adjustment is required for Darunavir/ritonavir during pregnancy and postpartum. Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.</p><p>Treatment with Darunavir/cobicistat 800/150 mg during pregnancy results in low Darunavir exposure. Therefore, therapy with Darunavir /cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir /cobicistat should be switched to an alternative regimen. Darunavir /ritonavir may be considered as an alternative.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Patients should be instructed to take Darunavir with cobicistat or low dose ritonavir within 30 minutes after completion of a meal. The type of food does not affect the exposure to Darunavir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
Patients with severe (Child-Pugh Class C) hepatic impairment.
Concomitant treatment with any of the following medicinal products given the expected decrease in plasma concentrations of Darunavir, ritonavir and cobicistat and the potential for loss of therapeutic effect.
Applicable to Darunavir boosted with either ritonavir or cobicistat:
- The combination product lopinavir/ritonavir
- The strong CYP3A inducers rifampicin and herbal preparations containing St John's wort (Hypericum perforatum). Coadministration is expected to reduce plasma concentrations of Darunavir; ritonavir and cobicistat, which could lead to loss of therapeutic effect and possible development of resistance.

Applicable to Darunavir boosted with cobicistat, not when boosted with ritonavir:
- Darunavir boosted with cobicistat is more sensitive for CYP3A induction than Darunavir boosted with ritonavir.
Concomitant use with strong CYP3A inducers is contraindicated, since these may reduce the exposure to cobicistat and Darunavir leading to loss of therapeutic effect. Strong CYP3A inducers include e.g. carbamazepine; phenobarbital and phenytoin.

Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the co-administered medicinal product. Therefore, concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (applies to Darunavir boosted with either ritonavir or cobicistat).

These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment.
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole.
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide.
- dabigatran, ticagrelor.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.</p><p>Regular assessment of virological response is advised. In the setting of lack or loss of virological response, resistance testing should be performed.</p><p>&nbsp;</p><p>Darunavir 400 mg or 800 mg must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.&nbsp; The Summary of Product Characteristics of cobicistat or ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with Darunavir.</p><p>&nbsp;</p><p>Increasing the dose of ritonavir from that recommended did not significantly affect Darunavir concentrations. It is not recommended to alter the dose of cobicistat or ritonavir.</p><p>&nbsp;</p><p>Darunavir binds predominantly to &alpha;1-acid glycoprotein. This protein binding is concentration-dependent indicative for saturation of binding. Therefore, protein displacement of medicinal products highly bound to &alpha;1-acid glycoprotein cannot be ruled out.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>ART-experienced patients &ndash; once daily dosing</u></p><p>Darunavir used in combination with cobicistat or low dose ritonavir once daily in ART-experienced patients should not be used in patients with one or more Darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA &ge; 100,000 copies/ml or CD4+ cell count &lt; 100 cells x 10<sup>6</sup>/l. Combinations with optimised background regimen (OBRs) other than &ge; 2 NRTIs have not been studied in this population. Limited data are available in patients with HIV-1clades other than B</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Darunavir is not recommended for use in paediatric patients below 3 years of age or less than 15 kg body weight.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Darunavir /ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk. Caution should be used in pregnant women with concomitant medications which may further decrease Darunavir exposure.</p><p>&nbsp;</p><p>Treatment with Darunavir/cobicistat 800/150 mg once daily during the second and third trimester has been shown to result in low Darunavir exposure, with a reduction of around 90% in C<sub>min</sub> levels.Cobicistat levels decrease and may not provide sufficient boosting. The substantial reduction in Darunavir exposure may result in virological failure and an increased risk of mother to child transmission of HIV infection. Therefore, therapy with Darunavir cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir /cobicistat should be switched to an alternative regimen. Darunavir given with low dose ritonavir may be considered as an alternative.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>As limited information is available on the use of Darunavir in patients aged 65 and over, caution should be exercised in the administration of Darunavir in elderly patients, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy.</p><p><u>Severe skin reactions </u></p><p>During the Darunavir/ritonavir clinical development program (N=3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens - Johnson syndrome has been rarely (&lt; 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported. Darunavir should be discontinued immediately if signs or symptoms of severe skin reactions develop. These can include, but are not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.</p><p>Rash occurred more commonly in treatment-experienced patients receiving regimens containing Darunavir /ritonavir + raltegravir compared to patients receiving Darunavir /ritonavir without raltegravir or raltegravir without Darunavir.</p><p>&nbsp;</p><p>Darunavir contains a sulphonamide moiety. Darunavir should be used with caution in patients with a known sulphonamide allergy.</p><p><u>&nbsp;</u></p><p><u>Hepatotoxicity</u></p><p>Drug-induced hepatitis (e.g. acute hepatitis, cytolytic hepatitis) has been reported with Darunavir. During the Darunavir/ritonavir clinical development program (N=3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with Darunavir /ritonavir. Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.</p><p>&nbsp;</p><p>Appropriate laboratory testing should be conducted prior to initiating therapy with Darunavir used in combination with cobicistat or low dose ritonavir and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of Darunavir used in combination with cobicistat or low dose ritonavir treatment.</p><p>&nbsp;</p><p>If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using Darunavir used in combination with cobicistat or low dose ritonavir, interruption or discontinuation of treatment should be considered promptly.</p><p>&nbsp;</p><p><u>Patients with coexisting conditions</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The safety and efficacy of Darunavir have not been established in patients with severe underlying liver disorders and Darunavir is therefore contraindicated in patients with severe hepatic impairment. Due to an increase in the unbound Darunavir plasma concentrations, Darunavir should be used with caution in patients with mild or moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No special precautions or dose adjustments for Darunavir/ritonavir are required in patients with renal impairment. As Darunavir and ritonavir are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis. Therefore, no special precautions or dose adjustments are required in these patients. Cobicistat has not been studied in patients receiving dialysis; therefore, no recommendation can be made for the use of Darunavir/cobicistat in these patients.</p><p>Cobicistat decreases the estimated creatinine clearance due to inhibition of tubular secretion of creatinine. This should be taken into consideration if Darunavir with cobicistat is administered to patients in whom the estimated creatinine clearance is used to adjust doses of co-administered medicinal products.</p><p>&nbsp;</p><p>There are currently inadequate data to determine whether co-administration of tenofovir disoproxil and cobicistat is associated with a greater risk of renal adverse reactions compared with regimens that include tenofovir disoproxil without cobicistat.</p><p>&nbsp;</p><p><em>Haemophiliac patients</em></p><p>There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued. A causal relationship has been suggested, although the mechanism of action has not been elucidated. Haemophiliac patients should, therefore, be made aware of the possibility of increased bleeding.</p><p><em>&nbsp;</em></p><p><em>Weight and metabolic parameters</em></p><p><em>&nbsp;</em></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><u>Osteonecrosis</u></p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><u>Immune reconstitution inflammatory syndrome</u></p><p>In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by <em>Pneumocystis jirovecii </em>(formerly known as <em>Pneumocystis carinii</em>). Any inflammatory symptoms should be evaluated and treatment instituted when necessary. In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with Darunavir co-administered with low dose ritonavir.</p><p>&nbsp;</p><p>Autoimmune disorders (such as Graves&#39; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><u>Interactions with medicinal products</u></p><p>Several of the interaction studies have been performed with Darunavir at lower than recommended doses. The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated. For full information on interactions with other medicinal products.</p><p>&nbsp;</p><p><em>Pharmacokinetic enhancer and concomitant medications</em></p><p><em>&nbsp;</em></p><p>Darunavir has different interaction profiles depending on whether the compound is boosted with ritonavir or cobicistat:</p><p>- Darunavir boosted with cobicistat is more sensitive for CYP3A induction: concomitant use of Darunavir/cobicistat and strong CYP3A inducers is therefore contraindicated and concomitant use with weak to moderate CYP3A inducers is not recommended. Concomitant use of Darunavir/ritonavir and Darunavir/cobicistat with lopinavir/ritonavir, rifampicin and herbal products containing St John&#39;s wort, <em>Hypericum perforatum</em>, is contraindicated.</p><p>&nbsp;</p><p>- Unlike ritonavir, cobicistat does not have inducing effects on enzymes or transport proteins. If switching the pharmacoenhancer from ritonavir to cobicistat, caution is required during the first two weeks of treatment with Darunavir/cobicistat, particularly if doses of any concomitantly administered medicinal products have been titrated or adjusted during use of ritonavir as a pharmacoenhancer. A dose reduction of the co-administered drug may be needed in these cases.</p><p>&nbsp;</p><p>Efavirenz in combination with Darunavir may result in sub-optimal Darunavir Cmin. If efavirenz is to be used in combination with Darunavir the Darunavir /ritonavir 600/100 mg twice daily regimen should be used. See the Summary of Product Characteristics for Darunavir 75 mg, 150 mg, 300 mg and 600 mg tablets.</p><p>&nbsp;</p><p>Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and P-glycoprotein.</p><p>&nbsp;</p><p>Darunavir 400 mg tablets contain sunset yellow FCF (E110) which may cause an allergic reaction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The interaction profile of Darunavir may differ depending on whether ritonavir or cobicistat is used as pharmacoenhancer.The recommendations given for concomitant use of Darunavir and other medicinal products may therefore differ depending on whether Darunavir is boosted with ritonavir or cobicistat and caution is also required during the first time of treatment if switching the pharmacoenhancer from ritonavir to cobicistat.</p><p>&nbsp;</p><p><u>Medicinal products that affect Darunavir exposure (ritonavir as pharmacoenhancer)</u></p><p>Darunavir and ritonavir are metabolised by CYP3A. Medicinal products that induce CYP3A activity would be expected to increase the clearance of Darunavir and ritonavir, resulting in lowered plasma concentrations of these compounds and consequently that of Darunavir, leading to loss of therapeutic effect and possible development of resistance. CYP3A inducers that are contraindicated include rifampicin, St John&#39;s wort and lopinavir.</p><p>&nbsp;</p><p>Co-administration of Darunavir and ritonavir with other medicinal products that inhibit CYP3A may decrease the clearance of Darunavir and ritonavir, which may result in increased plasma concentrations of Darunavir and ritonavir. Coadministration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, azole antifungals like clotrimazole).</p><p>&nbsp;</p><p><u>Medicinal products that affect Darunavir exposure (cobicistat as pharmacoenhancer)</u></p><p>Darunavir and cobicistat are metabolised by CYP3A, and co-administration with CYP3A inducers may therefore result in sub therapeutic plasma exposure to Darunavir. Darunavir boosted with cobicistat is more sensitive to CYP3A induction than ritonavir-boosted Darunavir: co-administration of Darunavir/cobicistat with medicinal products that are strong inducers of CYP3A (e.g. St John&#39;s wort, rifampicin, carbamazepine, phenobarbital, and phenytoin) is contraindicated. Co-administration of Darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, Nevirapine, boceprevir, fluticasone, and bosentan) is not recommended (see interaction table below).</p><p>&nbsp;</p><p>For co-administration with strong CYP3A4 inhibitors, the same recommendations apply independent of whether Darunavir is boosted with ritonavir or with cobicistat (see section above).</p><p>&nbsp;</p><p><u>Medicinal products that may be affected by Darunavir boosted with ritonavir</u></p><p>Darunavir and ritonavir are inhibitors of CYP3A, CYP2D6 and P-gp. Co-administration of Darunavir/ritonavir with medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.</p><p>&nbsp;</p><p>Darunavir co-administered with low dose ritonavir must not be combined with medicinal products that are highly dependent on CYP3A for clearance and for which increased systemic exposure is associated with serious and/or life threatening events (narrow therapeutic index)</p><p>The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of Darunavir when a single dose of 600 mg Darunavir was given orally in combination with ritonavir at 100 mg twice daily. Therefore, Darunavir must only be used in combination with a pharmacokinetic enhancer.</p><p>A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of Darunavir/ritonavir, which may be attributed to the presence of low dose ritonavir. Co-administration of Darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. Co-administration of Darunavir and ritonavir and medicinal products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.</p><p>&nbsp;</p><p>Although the effect on CYP2C8 has only been studied <em>in vitro</em>, co-administration of Darunavir and ritonavir and medicinal products primarily metabolised by CYP2C8 (such as paclitaxel, rosiglitazone, repaglinide) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.</p><p>Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates of these transporters can result in increased plasma concentrations of these compounds (e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction table below).</p><p><u>&nbsp;</u></p><p><u>Medicinal products that may be affected by Darunavir boosted with cobicistat</u></p><p>The recommendations for Darunavir boosted with ritonavir are adequate also for Darunavir boosted with cobicistat with regard to substrates of CYP3A4, CYP2D6, P-glycoprotein, OATP1B1 and OATP1B3 (see contraindications and recommendations presented in the section above). Cobicistat 150 mg given with Darunavir 800 mg once daily enhances Darunavir pharmacokinetic parameters in a comparable way to ritonavir.</p><p>&nbsp;</p><p>Unlike ritonavir, cobicistat does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. For further information on cobicistat, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Several of the interactions studies (indicated by #in the table below) have been performed at lower than recommended doses of Darunavir or with a different dosing regimen. The effects on co-administered doses of Darunavir or with a different dosing regimen. The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated.</p><p>&nbsp;</p><p>The interaction profile of Darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer. Darunavir may therefore have different recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat. No interaction studies presented in the table have been performed with Darunavir boosted with cobicistat. The same recommendations apply, unless specifically indicated. For further information on cobicistat, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p>Interactions between Darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range.</p><p>&nbsp;</p><p>In the table below the specific pharmacokinetic enhancer is specified when recommendations differ. When the recommendation is the same for Darunavir when co-administered with a low dose ritonavir or cobicistat, the term &ldquo;boosted Darunavir&rdquo; is used.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Medicinal products by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Interaction Geometric mean change (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HIV ANTIRETROVIRALS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Integrase strand transfer inhibitors</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dolutegravir</p></td><td style="vertical-align:top"><p>dolutegravir AUC &darr; 22%</p><p>dolutegravir C<sub>24h</sub>&nbsp;&darr; 38%</p><p>dolutegravir C<sub>max</sub>&nbsp;&darr; 11%</p><p>Darunavir &harr;*</p><p>* Using cross-study comparisons to historical pharmacokinetic data</p></td><td style="vertical-align:top"><p>Boosted Darunavir and dolutegravir can be used without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir</p></td><td style="vertical-align:top"><p>Some clinical studies suggest raltegravir may cause a modest decrease in Darunavir plasma concentrations.</p></td><td style="vertical-align:top"><p>At present the effect of raltegravir on Darunavir plasma concentrations does not appear to be clinically relevant. Boosted Darunavir and raltegravir can be used without dose adjustments.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Didanosine</p><p>400 mg once daily</p></td><td style="vertical-align:top"><p>didanosine AUC &darr; 9%</p><p>didanosine C<sub>min</sub>&nbsp;ND</p><p>didanosine C<sub>max</sub>&nbsp;&darr; 16%</p><p>Darunavir AUC &harr;</p><p>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>Boosted Darunavir and didanosine can be used without dose adjustments.</p><p>Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after boosted Darunavir given with food.</p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir disoproxil</p><p>245 mg once daily<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>tenofovir AUC &uarr; 22%</p><p>tenofovir C<sub>min</sub>&nbsp;&uarr; 37%</p><p>tenofovir C<sub>max</sub>&nbsp;&uarr; 24%</p><p><sup>#</sup>Darunavir AUC &uarr; 21%</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&uarr; 24%</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&uarr; 16%</p><p>(&uarr; tenofovir from effect on MDR-1 transport in the renal tubules)</p></td><td style="vertical-align:top"><p>Monitoring of renal function may be indicated when boosted Darunavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.</p><p>Darunavir co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil.</p></td></tr><tr><td style="vertical-align:top"><p>Emtricitabine/tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Tenofovir alafenamide &harr;</p><p>Tenofovir &uarr;</p></td><td style="vertical-align:top"><p>The recommended dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted Darunavir</p></td></tr><tr><td style="vertical-align:top"><p>Abacavir</p><p>Emtricitabine</p><p>Lamivudine</p><p>Stavudine</p><p>Zidovudine</p></td><td style="vertical-align:top"><p>Not studied. Based on the different elimination pathways of the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are primarily renally excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and boosted Darunavir.</p></td><td style="vertical-align:top"><p>Boosted Darunavir can be used with these NRTIs without dose adjustment.</p><p>Darunavir co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of emtricitabine or lamivudine.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz</p><p>600 mg once daily</p></td><td style="vertical-align:top"><p>efavirenz AUC &uarr; 21%</p><p>efavirenz C<sub>min</sub>&nbsp;&uarr; 17%</p><p>efavirenz C<sub>max</sub>&nbsp;&uarr; 15%</p><p><sup>#</sup>Darunavir AUC &darr; 13%</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&darr; 31%</p><p><sup>#</sup>Darunavir C<sub>max&nbsp;</sub>&darr; 15%</p><p>(&uarr; efavirenz from CYP3A inhibition)</p><p>(&darr; Darunavir from CYP3A induction)</p></td><td style="vertical-align:top"><p>Clinical monitoring for central nervous system toxicity associated with increased exposure to efavirenz may be indicated when Darunavir co-administered with low dose ritonavir is given in combination with efavirenz.</p><p>Efavirenz in combination with Darunavir /ritonavir 800/100 mg once daily may result in sub-optimal Darunavir C<sub>min</sub>. If efavirenz is to be used in combination with Darunavir /ritonavir, the Darunavir /ritonavir 600/100 mg twice daily regimen should be used.</p><p>Co-administration with Darunavir co-administered with cobicistat is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Etravirine</p><p>100 mg twice daily</p></td><td style="vertical-align:top"><p>etravirine AUC &darr; 37%</p><p>etravirine C<sub>min</sub>&nbsp;&darr; 49%</p><p>etravirine C<sub>max&nbsp;</sub>&darr; 32%</p><p>Darunavir AUC &uarr; 15%</p><p>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>Darunavir co-administered with low dose ritonavir and etravirine 200 mg twice daily can be used without dose adjustments.</p><p>Co-administration with Darunavir co-administered with cobicistat is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine</p><p>200 mg twice daily</p></td><td style="vertical-align:top"><p>nevirapine AUC &uarr; 27%</p><p>nevirapine C<sub>min</sub>&nbsp;&uarr; 47%</p><p>nevirapine C<sub>max</sub>&nbsp;&uarr; 18%</p><p><sup>#</sup>Darunavir: concentrations were consistent with historical data</p><p>(&uarr; nevirapine from CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Darunavir co-administered with low dose ritonavir and nevirapine can be used without dose adjustments.</p><p>Co-administration with Darunavir co-administered with cobicistat is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Rilpivirine</p><p>150 mg once daily</p></td><td style="vertical-align:top"><p>rilpivirine AUC &uarr; 130%</p><p>rilpivirine C<sub>min</sub>&nbsp;&uarr; 178%</p><p>rilpivirine C<sub>max</sub>&nbsp;&uarr; 79%</p><p>Darunavir AUC &harr;</p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 11%</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>Boosted Darunavir and rilpivirine can be used without dose adjustments.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV Protease inhibitors (PIs) - without additional co-administration of low dose ritonavir</em></strong><sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir</p><p>300 mg once daily</p></td><td style="vertical-align:top"><p>atazanavir AUC &harr;</p><p>atazanavir C<sub>min</sub>&nbsp;&uarr; 52%</p><p>atazanavir C<sub>max</sub>&nbsp;&darr; 11%</p><p><sup>#</sup>Darunavir AUC &harr;</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&harr;</p><p>Atazanavir: comparison of atazanavir/ritonavir 300/100 mg once daily vs. atazanavir 300 mg once daily in combination with Darunavir/ritonavir 400/100 mg twice daily.</p><p>Darunavir: comparison of Darunavir/ritonavir 400/100 mg twice daily vs. Darunavir/ritonavir 400/100 mg twice daily in combination with atazanavir 300 mg once daily.</p></td><td style="vertical-align:top"><p>Darunavir co-administered with low dose ritonavir and atazanavir can be used without dose adjustments.</p><p>Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co-administration with an inhibitor of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir</p><p>800 mg twice daily</p></td><td style="vertical-align:top"><p>indinavir AUC &uarr; 23%</p><p>indinavir C<sub>min</sub>&nbsp;&uarr; 125%</p><p>indinavir C<sub>max</sub>&nbsp;&harr;</p><p><sup>#</sup>Darunavir AUC &uarr; 24%</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&uarr; 44%</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&uarr; 11%</p><p>Indinavir: comparison of indinavir/ritonavir 800/100 mg twice daily vs. indinavir/Darunavir/ritonavir 800/400/100 mg twice daily.</p><p>Darunavir: comparison of Darunavir/ritonavir 400/100 mg twice daily vs. Darunavir/ritonavir 400/100 mg in combination with indinavir 800 mg twice daily.</p></td><td style="vertical-align:top"><p>When used in combination with Darunavir co-administered with low dose ritonavir, dose adjustment of indinavir from 800 mg twice daily to 600 mg twice daily may be warranted in case of intolerance.</p><p>Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co-administration with an inhibitor of CYP3A4.</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir</p><p>1,000 mg twice daily</p></td><td style="vertical-align:top"><p><sup>#</sup>Darunavir AUC &darr; 26%</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&darr; 42%</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&darr; 17%</p><p>saquinavir AUC &darr; 6%</p><p>saquinavir C<sub>min</sub>&nbsp;&darr; 18%</p><p>saquinavir C<sub>max</sub>&nbsp;&darr; 6%</p><p>Saquinavir: comparison of saquinavir/ritonavir 1,000/100 mg twice daily vs. saquinavir/Darunavir/ritonavir 1,000/400/100 mg twice daily</p><p>Darunavir: comparison of Darunavir/ritonavir 400/100 mg twice daily vs. Darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily.</p></td><td style="vertical-align:top"><p>It is not recommended to combine Darunavir co-administered with low dose ritonavir with saquinavir.</p><p>Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co-administration with an inhibitor of CYP3A4.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir</em></strong><strong><sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir</p><p>400/100 mg twice daily</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Lopinavir/ritonavir</p><p>533/133.3 mg twice daily</p></td><td style="vertical-align:top"><p>lopinavir AUC &uarr; 9%</p><p>lopinavir C<sub>min</sub>&nbsp;&uarr; 23%</p><p>lopinavir C<sub>max</sub>&nbsp;&darr; 2%</p><p>Darunavir AUC &darr; 38%<sup>&Dagger;</sup></p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 51%<sup>&Dagger;</sup></p><p>Darunavir C<sub>max</sub>&nbsp;&darr; 21%<sup>&Dagger;</sup></p><p>lopinavir AUC &harr;</p><p>lopinavir C<sub>min</sub>&nbsp;&uarr; 13%</p><p>lopinavir C<sub>max</sub>&nbsp;&uarr; 11%</p><p>Darunavir AUC &darr; 41%</p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 55%</p><p>Darunavir C<sub>max</sub>&nbsp;&darr; 21%</p><p><sup>&Dagger;&nbsp;</sup>based upon non dose normalised values</p></td><td style="vertical-align:top"><p>Due to a decrease in the exposure (AUC) of Darunavir by 40%, appropriate doses of the combination have not been established. Hence, concomitant use of boosted Darunavir and the combination product lopinavir/ritonavir is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CCR5 ANTAGONIST</strong></p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc</p><p>150 mg twice daily</p></td><td style="vertical-align:top"><p>maraviroc AUC &uarr; 305%</p><p>maraviroc C<sub>min</sub>&nbsp;ND</p><p>maraviroc C<sub>max</sub>&nbsp;&uarr; 129%</p><p>Darunavir, ritonavir concentrations were consistent with historical data</p></td><td style="vertical-align:top"><p>The maraviroc dose should be 150 mg twice daily when co-administered with boosted Darunavir</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&alpha;1-ADRENORECEPTOR ANTAGONIST</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin</p></td><td style="vertical-align:top"><p>Based on theoretical considerations Darunavir is expected to increase alfuzosin plasma concentrations.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Co-administration of boosted Darunavir and alfuzosin is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANAESTHETIC</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alfentanil</p></td><td style="vertical-align:top"><p>Not studied. The metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited by boosted Darunavir</p></td><td style="vertical-align:top"><p>The concomitant use with boosted Darunavir may require to lower the dose of alfentanil and requires monitoring for risks of prolonged or delayed respiratory depression.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIANGINA/ANTIARRHYTHMIC</strong></p></td></tr><tr><td style="vertical-align:top"><p>Disopyramide</p><p>Flecainide</p><p>Lidocaine (systemic)</p><p>Mexiletine</p><p>Propafenone</p><p>&nbsp;</p><p>Amiodarone</p><p>Bepridil</p><p>Dronedarone</p><p>Quinidine</p><p>Ranolazine</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir is expected to increase these antiarrhythmic plasma concentrations.</p><p>(CYP3A and/or CYP2D6 inhibition)</p></td><td style="vertical-align:top"><p>Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when co-administered with boosted Darunavir.</p><p>&nbsp;</p><p>Boosted Darunavir and amiodarone, bepridil, dronedarone, quinidine, or ranolazine is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p><p>0.4 mg single dose</p></td><td style="vertical-align:top"><p>digoxin AUC &uarr; 61%</p><p>digoxin C<sub>min</sub>&nbsp;ND</p><p>digoxin C<sub>max</sub>&nbsp;&uarr; 29%</p><p>(&uarr; digoxin from probable inhibition of P-gp)</p></td><td style="vertical-align:top"><p>Given that digoxin has a narrow therapeutic index, it is recommended that the lowest possible dose of digoxin should initially be prescribed in case digoxin is given to patients on boosted Darunavir therapy. The digoxin dose should be carefully titrated to obtain the desired clinical effect while assessing the overall clinical state of the subject.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIBIOTIC</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>clarithromycin AUC &uarr; 57%</p><p>clarithromycin C<sub>min</sub>&nbsp;&uarr; 174%</p><p>clarithromycin C<sub>max</sub>&nbsp;&uarr; 26%</p><p><sup>#</sup>Darunavir AUC &darr; 13%</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&uarr; 1%</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&darr; 17%</p><p>14-OH-clarithromycin concentrations were not detectable when combined with Darunavir /ritonavir.</p><p>(&uarr; clarithromycin from CYP3A inhibition and possible P-gp inhibition)</p></td><td style="vertical-align:top"><p>Caution should be exercised when clarithromycin is combined with boosted Darunavir</p><p>For patients with renal impairment the Summary of Product Characteristics for clarithromycin should be consulted for the recommended dose.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR</strong></p></td></tr><tr><td style="vertical-align:top"><p>Apixaban</p><p>Edoxaban</p><p>Rivaroxaban</p></td><td style="vertical-align:top"><p>Not studied. Co-administration of boosted Darunavir with these anticoagulants may increase concentrations of the anticoagulant, which may lead to an increased bleeding risk.</p><p>(CYP3A and/or P-gp inhibition)</p></td><td style="vertical-align:top"><p>The use of boosted Darunavir and these anticoagulants is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Dabigatran</p><p>Ticagrelor</p></td><td style="vertical-align:top"><p>Not studied. Co-administration with boosted Darunavir may lead to a substantial increase in exposure to dabigatran or ticagrelor.</p></td><td style="vertical-align:top"><p>Concomitant administration of boosted Darunavir with dabigatran or ticagrelor is contraindicated.</p><p>Use of other antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Warfarin</p></td><td style="vertical-align:top"><p>Not studied. Warfarin concentrations may be affected when co-administered with boosted Darunavir.</p></td><td style="vertical-align:top"><p>It is recommended that the international normalised ratio (INR) be monitored when warfarin is combined with boosted Darunavir</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTICONVULSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital</p><p>Phenytoin</p></td><td style="vertical-align:top"><p>Not studied. Phenobarbital and phenytoin are expected to decrease plasma concentrations of Darunavir and its pharmacoenhancer.</p><p>(induction of CYP450 enzymes)</p></td><td style="vertical-align:top"><p>Darunavir co-administered with low dose ritonavir should not be used in combination with these medicines.</p><p>The use of these medicines with Darunavir /cobicistat is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p><p>200 mg twice daily</p></td><td style="vertical-align:top"><p>carbamazepine AUC &uarr; 45%</p><p>carbamazepine C<sub>min</sub>&nbsp;&uarr; 54%</p><p>carbamazepine C<sub>max</sub>&nbsp;&uarr; 43%</p><p>Darunavir AUC &harr;</p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 15%</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment for Darunavir /ritonavir is recommended. If there is a need to combine Darunavir /ritonavir and carbamazepine, patients should be monitored for potential carbamazepine-related adverse events. Carbamazepine concentrations should be monitored and its dose should be titrated for adequate response. Based upon the findings, the carbamazepine dose may need to be reduced by 25% to 50% in the presence of Darunavir /ritonavir.</p><p>The use of carbamazepine with Darunavir co-administered with cobicistat is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>Clonazepam</p></td><td style="vertical-align:top"><p>Not studied. Co-administration of boosted Darunavir with clonazepam may increase concentrations of clonazepam. (CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Clinical monitoring is recommended when co-administering boosted Darunavir and clonazepam.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIDEPRESSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Paroxetine</p><p>20 mg once daily</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Sertraline</p><p>50 mg once daily</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Amitriptyline</p><p>Desipramine</p><p>Imipramine</p><p>Nortriptyline</p><p>Trazodone</p></td><td style="vertical-align:top"><p>paroxetine AUC &darr; 39%</p><p>paroxetine C<sub>min</sub>&nbsp;&darr; 37%</p><p>paroxetine C<sub>max</sub>&nbsp;&darr; 36%</p><p><sup>#</sup>Darunavir AUC &harr;</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&harr;</p><p>sertraline AUC &darr; 49%</p><p>sertraline C<sub>min</sub>&nbsp;&darr; 49%</p><p>sertraline C<sub>max</sub>&nbsp;&darr; 44%</p><p><sup>#</sup>Darunavir AUC &harr;</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&darr; 6%</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&harr;</p><p>In contrast to these data with Darunavir /ritonavir, Darunavir /cobicistat may increase these antidepressant plasma concentrations (CYP2D6 and/or CYP3A inhibition).</p><p>Concomitant use of boosted Darunavir and these antidepressants may increase concentrations of the antidepressant.</p><p>(CYP2D6 and/or CYP3A inhibition)</p></td><td style="vertical-align:top"><p>If antidepressants are co-administered with boosted Darunavir, the recommended approach is a dose titration of the antidepressant based on a clinical assessment of antidepressant response. In addition, patients on a stable dose of these antidepressants who start treatment with boosted Darunavir should be monitored for antidepressant response.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Clinical monitoring is recommended when co-administering boosted Darunavir with these antidepressants and a dose adjustment of the antidepressant may be needed.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTI-DIABETICS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>Not studied. Based on theoretical considerations Darunavir co-administered with cobicistat is expected to increase metformin plasma concentrations.</p><p>(MATE1 inhibition)</p></td><td style="vertical-align:top"><p>Careful patient monitoring and dose adjustment of metformin is recommended in patients who are taking Darunavir co-administered with cobicistat.</p><p>(not applicable for Darunavir co-administered with ritonavir)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIEMETICS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Domperidone</p></td><td style="vertical-align:top"><p>Not studied</p></td><td style="vertical-align:top"><p>Co-administration of domperidone with boosted Darunavir is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIFUNGALS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Voriconazole</p></td><td style="vertical-align:top"><p>Not studied. Ritonavir may decrease plasma concentrations of voriconazole.</p><p>(induction of CYP450 enzymes)</p><p>Concentrations of voriconazole may increase or decrease when co-administered with Darunavir co-administered with cobicistat.</p><p>(inhibition of CYP450 enzymes)</p></td><td style="vertical-align:top"><p>Voriconazole should not be combined with boosted Darunavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p><p>Isavuconazole</p><p>Itraconazole</p><p>Posaconazole</p><p><sub>&nbsp;</sub></p><p>Clotrimazole</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir may increase antifungal plasma concentrations and posaconazole, isavuconazole, itraconazole or fluconazole may increase Darunavir concentrations.</p><p>(CYP3A and/or P-gp inhibition)</p><p>Not studied. Concomitant systemic use of clotrimazole and boosted Darunavir may increase plasma concentrations of Darunavir and/or clotrimazole.</p><p>Darunavir AUC<sub>24h</sub>&nbsp;&uarr; 33% (based on population pharmacokinetic model)</p></td><td style="vertical-align:top"><p>Caution is warranted and clinical monitoring is recommended.</p><p>When co-administration is required the daily dose of itraconazole should not exceed 200 mg.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIGOUT MEDICINES</strong></p></td></tr><tr><td style="vertical-align:top"><p>Colchicine</p></td><td style="vertical-align:top"><p>Not studied. Concomitant use of colchicine and boosted Darunavir may increase the exposure to colchicine.</p><p>(CYP3A and/ or P-gp inhibition)</p></td><td style="vertical-align:top"><p>A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with boosted Darunavir is required. For patients with renal or hepatic impairment colchicine with boosted Darunavir is contraindicated</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIMALARIALS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Artemether/Lumefantrine</p><p>80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours</p></td><td style="vertical-align:top"><p>artemether AUC &darr; 16%</p><p>artemether C<sub>min</sub>&nbsp;&harr;</p><p>artemether C<sub>max</sub>&nbsp;&darr; 18%</p><p>dihydroartemisinin AUC &darr; 18%</p><p>dihydroartemisinin C<sub>min</sub>&nbsp;&harr;</p><p>dihydroartemisinin C<sub>max</sub>&nbsp;&darr; 18%</p><p>lumefantrine AUC &uarr; 175%</p><p>lumefantrine C<sub>min</sub>&nbsp;&uarr; 126%</p><p>lumefantrine C<sub>max</sub>&nbsp;&uarr; 65%</p><p>Darunavir AUC &harr;</p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 13%</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>The combination of boosted Darunavir and artemether/ lumefantrine can be used without dose adjustments; however, due to the increase in lumefantrine exposure, the combination should be used with caution.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIMYCOBACTERIALS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin</p><p>Rifapentine</p></td><td style="vertical-align:top"><p>Not studied. Rifapentine and rifampicin are strong CYP3A inducers and have been shown to cause profound decreases in concentrations of other protease inhibitors, which can result in virological failure and resistance development (CYP450 enzyme induction). During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin.</p></td><td style="vertical-align:top"><p>The combination of rifapentine and boosted Darunavir is not recommended.</p><p>The combination of rifampicin and boosted Darunavir is contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p>150 mg once every other day</p></td><td style="vertical-align:top"><p>rifabutin AUC** &uarr; 55%</p><p>rifabutin C<sub>min</sub>** &uarr; ND</p><p>rifabutin C<sub>max</sub>** &harr;</p><p>Darunavir AUC &uarr; 53%</p><p>Darunavir C<sub>min</sub>&nbsp;&uarr; 68%</p><p>Darunavir C<sub>max</sub>&nbsp;&uarr; 39%</p><p>** sum of active moieties of rifabutin (parent drug + 25-<em>O-</em>desacetyl metabolite)</p><p>The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg once daily alone and 150 mg once every other day in combination with Darunavir /ritonavir (600/100 mg twice daily) with an about 10-fold increase in the daily exposure to the active metabolite 25-<em>O-</em>desacetylrifabutin. Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-<em>O-</em>desacetyl metabolite) was increased 1.6-fold, while C<sub>max</sub>&nbsp;remained comparable.</p><p>Data on comparison with a 150 mg once daily reference dose is lacking.</p><p>(Rifabutin is an inducer and substrate of CYP3A.) An increase of systemic exposure to Darunavir was observed when Darunavir co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).</p></td><td style="vertical-align:top"><p>A dosage reduction of rifabutin by 75% of the usual dose of 300 mg/day (i.e. rifabutin 150 mg once every other day) and increased monitoring for rifabutin related adverse events is warranted in patients receiving the combination with Darunavir co-administered with ritonavir. In case of safety issues, a further increase of the dosing interval for rifabutin and/or monitoring of rifabutin levels should be considered.</p><p>Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients.</p><p>Based upon the safety profile of Darunavir ritonavir, the increase in Darunavir exposure in the presence of rifabutin does not warrant a dose adjustment for Darunavir /ritonavir.</p><p>Based on pharmacokinetic modeling, this dosage reduction of 75% is also applicable if patients receive rifabutin at doses other than 300 mg/day.</p><p>Co-administration of Darunavir co-administered with cobicistat and rifabutin is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTINEOPLASTICS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dasatinib</p><p>Nilotinib</p><p>Vinblastine</p><p>Vincristine</p><p>Everolimus</p><p>Irinotecan</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir is expected to increase these antineoplastic plasma concentrations.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Concentrations of these medicinal products may be increased when co-administered with boosted Darunavir resulting in the potential for increased adverse events usually associated with these agents.</p><p>Caution should be exercised when combining one of these antineoplastic agents with boosted Darunavir Concominant use of everolimus and boosted Darunavir is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ANTIPSYCHOTICS/NEUROLEPTICS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Quetiapine</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir is expected to increase these antipsychotic plasma concentrations.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Concomitant administration of boosted Darunavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity. Increased concentrations of quetiapine may lead to coma.</p></td></tr><tr><td style="vertical-align:top"><p>Perphenazine</p><p>Risperidone</p><p>Thioridazine</p><p>Lurasidone</p><p>Pimozide</p><p>Sertindole</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir is expected to increase these antipsychotic plasma concentrations.</p><p>(CYP3A, CYP2D6 and/or P-gp inhibition)</p></td><td style="vertical-align:top"><p>A dose decrease may be needed for these drugs when co-administered with boosted Darunavir</p><p>Concominant administration of boosted Darunavir and lurasidone, pimozide or sertindole is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&beta;-BLOCKERS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Carvedilol</p><p>Metoprolol</p><p>Timolol</p></td><td style="vertical-align:top"><p>Not Studied. Boosted Darunavir is expected to increase these &beta;-blocker plasma concentrations.</p><p>(CYP2D6 inhibition)</p></td><td style="vertical-align:top"><p>Clinical monitoring is recommended when co-administering boosted Darunavir with &beta;-blockers. A lower dose of the &beta;-blocker should be considered.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CALCIUM CHANNEL BLOCKERS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Amlodipine</p><p>Diltiazem</p><p>Felodipine</p><p>Nicardipine</p><p>Nifedipine</p><p>Verapamil</p></td><td style="vertical-align:top"><p>Not studied. Boosted Darunavir can be expected to increase the plasma concentrations of calcium channel blockers.</p><p>(CYP3A and/or CYP2D6 inhibition)</p></td><td style="vertical-align:top"><p>Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with boosted Darunavir.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>CORTICOSTEROIDS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone)</p></td><td style="vertical-align:top"><p>Fluticasone: in a clinical study where ritonavir 100 mg capsules twice daily were co-administered with 50 &mu;g intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 82-89%). Greater effects may be expected when fluticasone is inhaled. Systemic corticosteroid effects including Cushing&#39;s syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone. The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown.</p><p>Other corticosteroids: interaction not studied. Plasma concentrations of these medicinal products may be increased when co-administered with boosted Darunavir resulting in reduced serum cortisol concentrations.</p></td><td style="vertical-align:top"><p>Concomitant use of boosted Darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing&#39;s syndrome and adrenal suppression.</p><p>Co-administration with CYP3A-metabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects.</p><p>Alternative corticosteroids which are less dependent on CYP3A metabolism e.g. beclomethasone for intranasal or inhalational use should be considered, particularly for long term use.</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone (systemic)</p></td><td style="vertical-align:top"><p>Not studied. Dexamethasone may decrease plasma concentrations of Darunavir.</p><p>(CYP3A induction)</p></td><td style="vertical-align:top"><p>Systemic dexamethasone should be used with caution when combined with boosted Darunavir</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ENDOTHELIN RECEPTOR ANTAGONISTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bosentan</p></td><td style="vertical-align:top"><p>Not studied. Concomitant use of bosentan and boosted Darunavir may increase plasma concentrations of bosentan.</p><p>Bosentan is expected to decrease plasma concentrations of Darunavir and/or its pharmacoenhancer.</p><p>(CYP3A induction)</p></td><td style="vertical-align:top"><p>When administered concomitantly with Darunavir and low dose ritonavir, the patient&#39;s tolerability of bosentan should be monitored.</p><p>Co-administration of Darunavir co-administered with cobicistat and bosentan is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>NS3-4A protease inhibitors</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Elbasvir/grazoprevir</p></td><td style="vertical-align:top"><p>Boosted Darunavir may increase the exposure to grazoprevir.</p><p>(CYP3A and OATP1B inhibition)</p></td><td style="vertical-align:top"><p>Concomitant use of boosted Darunavir and elbasvir/grazoprevir is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>Boceprevir</p><p>800 mg three times daily</p></td><td style="vertical-align:top"><p>boceprevir AUC &darr; 32%</p><p>boceprevir C<sub>min</sub>&nbsp;&darr; 35%</p><p>boceprevir C<sub>max</sub>&nbsp;&darr; 25%</p><p>Darunavir AUC &darr; 44%</p><p>Darunavir C<sub>min</sub>&nbsp;&darr; 59%</p><p>Darunavir C<sub>max</sub>&nbsp;&darr; 36%</p></td><td style="vertical-align:top"><p>It is not recommended to co-administer boosted Darunavir and boceprevir.</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir/pibrentasvir</p></td><td style="vertical-align:top"><p>Based on theoretical considerations boosted Darunavir may increase the exposure to glecaprevir and pibrentasvir. (P gp, BCRP and/or OATP1B1/3 inhibition)</p></td><td style="vertical-align:top"><p>It is not recommended to co-administer boosted Darunavir with glecaprevir/pibrentasvir.</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir</p></td><td style="vertical-align:top"><p>simeprevir AUC &uarr; 159%</p><p>simeprevir C<sub>min</sub>&nbsp;&uarr; 358%</p><p>simeprevir C<sub>max</sub>&nbsp;&uarr; 79%</p><p>Darunavir AUC &uarr; 18%</p><p>Darunavir C<sub>min</sub>&nbsp;&uarr; 31%</p><p>Darunavir C<sub>max</sub>&nbsp;&harr;</p><p>The dose of simeprevir in this interaction study was 50 mg when co-administered in combination with Darunavir/ritonavir, compared to 150 mg in the simeprevir alone treatment group.</p></td><td style="vertical-align:top"><p>It is not recommended to co-administer boosted Darunavir and simeprevir.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HERBAL PRODUCTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>St John&#39;s wort&nbsp;<em>(Hypericum perforatum)</em></p></td><td style="vertical-align:top"><p>Not studied. St John&#39;s wort is expected to decrease the plasma concentrations of Darunavir or its pharmacoenhancers.</p><p>(CYP450 induction)</p></td><td style="vertical-align:top"><p>Boosted Darunavir must not be used concomitantly with products containing St John&#39;s wort (<em>Hypericum perforatum</em>). If a patient is already taking St John&#39;s wort, stop St John&#39;s wort and if possible check viral levels. Darunavir exposure (and also ritonavir exposure) may increase on stopping St John&#39;s wort. The inducing effect may persist for at least 2 weeks after cessation of treatment with St John&#39;s wort.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HMG CO-A REDUCTASE INHIBITORS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lovastatin</p><p>Simvastatin</p></td><td style="vertical-align:top"><p>Not studied. Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when co-administered with boosted Darunavir (CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Increased plasma concentrations of lovastatin or simvastatin may cause myopathy, including rhabdomyolysis. Concomitant use of boosted Darunavir with lovastatin and simvastatin is therefore contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin</p><p>10 mg once daily</p></td><td style="vertical-align:top"><p>atorvastatin AUC &uarr; 3-4 fold</p><p>atorvastatin C<sub>min</sub>&nbsp;&uarr; &asymp;5.5-10 fold</p><p>atorvastatin C<sub>max</sub>&nbsp;&uarr; &asymp;2 fold</p><p><sup>#</sup>Darunavir/ritonavir</p><p>atorvastatin AUC &uarr; 290%<sup>&nbsp;&Omega;</sup></p><p>atorvastatin C<sub>max</sub>&nbsp;&uarr; 319%<sup>&nbsp;&Omega;</sup></p><p>atorvastatin C<sub>min</sub>&nbsp;ND<sup>&nbsp;&Omega;</sup></p><p><sup>&Omega;&nbsp;</sup>with Darunavir/cobicistat 800/150 mg</p></td><td style="vertical-align:top"><p>When administration of atorvastatin and boosted Darunavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily. A gradual dose increase of atorvastatin may be tailored to the clinical response.</p></td></tr><tr><td style="vertical-align:top"><p>Pravastatin</p><p>40 mg single dose</p></td><td style="vertical-align:top"><p>pravastatin AUC &uarr; 81%<sup>&para;</sup></p><p>pravastatin C<sub>min</sub>&nbsp;ND</p><p>pravastatin C<sub>max</sub>&nbsp;&uarr; 63%</p><p><sup>&para;&nbsp;</sup>an up to five-fold increase was seen in a limited subset of subjects</p></td><td style="vertical-align:top"><p>When administration of pravastatin and boosted Darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin</p><p>10 mg once daily</p></td><td style="vertical-align:top"><p>rosuvastatin AUC &uarr; 48%<sup>║</sup></p><p>rosuvastatin C<sub>max</sub>&nbsp;&uarr; 144%<sup>║</sup></p><p><sup>║</sup>&nbsp;based on published data with Darunavir/ritonavir</p><p>rosuvastatin AUC &uarr; 93%<sup>&sect;</sup></p><p>rosuvastatin C<sub>max</sub>&nbsp;&uarr; 277%<sup>&sect;</sup></p><p>rosuvastatin C<sub>min</sub>&nbsp;ND<sup>&sect;</sup></p><p><sup>&sect;&nbsp;</sup>with Darunavir/cobicistat 800/150 mg</p></td><td style="vertical-align:top"><p>When administration of rosuvastatin and boosted Darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OTHER LIPID MODIFYING AGENTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lomitapide</p></td><td style="vertical-align:top"><p>Based on theoretical considerations boosted Darunavir is expected to increase the exposure of lomitapide when co-administered.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Co-administration is contraindicated</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>H<sub>2</sub>-RECEPTOR ANTAGONISTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine</p><p>150 mg twice daily</p></td><td style="vertical-align:top"><p><sup>#</sup>Darunavir AUC &harr;</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>Boosted Darunavir can be co-administered with H<sub>2</sub>-receptor antagonists without dose adjustments.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>IMMUNOSUPPRESSANTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin</p><p>Sirolimus</p><p>Tacrolimus</p><p>&nbsp;</p><p>Everolimus</p></td><td style="vertical-align:top"><p>Not studied. Exposure to these immune suppressants will be increased when co-administered with boosted Darunavir.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.</p><p>&nbsp;</p><p>Concomitant use of everolimus and boosted Darunavir is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>INHALED BETA AGONISTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol</p></td><td style="vertical-align:top"><p>Not studied. Concomitant use of salmeterol and boosted Darunavir may increase plasma concentrations of salmeterol.</p></td><td style="vertical-align:top"><p>Concomitant use of salmeterol and boosted Darunavir is not recommended. The combination may result in increased risk of cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methadone</p><p>individual dose ranging from 55 mg to 150 mg once daily</p></td><td style="vertical-align:top"><p>R(-) methadone AUC &darr; 16%</p><p>R(-) methadone C<sub>min</sub>&nbsp;&darr; 15%</p><p>R(-) methadone C<sub>max</sub>&nbsp;&darr; 24%</p><p>Darunavir /cobicistat may, in contrast, increase methadone plasma concentrations (see cobicistat SmPC).</p></td><td style="vertical-align:top"><p>No adjustment of methadone dosage is required when initiating co-administration with boosted Darunavir However, adjustment of the methadone dose may be necessary when concomitantly administered for a longer period of time. Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients.</p></td></tr><tr><td style="vertical-align:top"><p>Buprenorphine/naloxone</p><p>8/2 mg&ndash;16/4 mg once daily</p></td><td style="vertical-align:top"><p>buprenorphine AUC &darr; 11%</p><p>buprenorphine C<sub>min</sub>&nbsp;&harr;</p><p>buprenorphine C<sub>max</sub>&nbsp;&darr; 8%</p><p>norbuprenorphine AUC &uarr; 46%</p><p>norbuprenorphine C<sub>min&nbsp;</sub>&uarr; 71%</p><p>norbuprenorphine C<sub>max</sub>&nbsp;&uarr; 36%</p><p>naloxone AUC &harr;</p><p>naloxone C<sub>min</sub>&nbsp;ND</p><p>naloxone C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>The clinical relevance of the increase in nor buprenorphine pharmacokinetic parameters has not been established. Dose adjustment for buprenorphine may not be necessary when co-administered with boosted Darunavir but a careful clinical monitoring for signs of opiate toxicity is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fentanyl</p><p>Oxycodone</p><p>Tramadol</p></td><td style="vertical-align:top"><p>Based on theoretical considerations boosted Darunavir may increase plasma concentrations of these analgesics.</p><p>(CYP2D6 and/or CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Clinical monitoring is recommended when co-administering boosted Darunavir with these analgesics.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OESTROGEN-BASED CONTRACEPTIVES</strong></p></td></tr><tr><td style="vertical-align:top"><p>Drospirenone Ethinylestradiol (3 mg/0.02 mg once daily)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ethinylestradiol</p><p>Norethindrone</p><p>35 &mu;g/1 mg once daily</p></td><td style="vertical-align:top"><p>drospirenone AUC &uarr; 58%<sup>&euro;</sup></p><p>drospirenone C<sub>min</sub>&nbsp;ND<sup>&euro;</sup></p><p>drospirenone C<sub>max</sub>&nbsp;&uarr; 15%<sup>&euro;</sup></p><p>ethinylestradiol AUC &darr; 30%<sup>&euro;</sup></p><p>ethinylestradiol C<sub>min</sub>&nbsp;ND<sup>&euro;</sup></p><p>ethinylestradiol C<sub>max</sub>&nbsp;&darr; 14%<sup>&euro;</sup></p><p><sup>&euro;&nbsp;</sup>with Darunavir/cobicistat</p><p>ethinylestradiol AUC &darr; 44%<sup>&beta;</sup></p><p>ethinylestradiol C<sub>min</sub>&nbsp;&darr; 62%<sup>&beta;</sup></p><p>ethinylestradiol C<sub>max</sub>&nbsp;&darr; 32%<sup>&beta;</sup></p><p>norethindrone AUC &darr; 14%<sup>&beta;</sup></p><p>norethindrone C<sub>min</sub>&nbsp;&darr; 30%<sup>&beta;</sup></p><p>norethindrone C<sub>max</sub>&nbsp;&harr;<sup>&beta;</sup></p><p><sup>&beta;&nbsp;</sup>with Darunavir/ritonavir</p></td><td style="vertical-align:top"><p>When Darunavir is co-administered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia.</p><p>Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered with boosted Darunavir Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OPIOID ANTAGONIST</strong></p></td></tr><tr><td style="vertical-align:top"><p>Naloxegol</p></td><td style="vertical-align:top"><p>Not studied.</p></td><td style="vertical-align:top"><p>Co-administration of boosted</p><p>Darunavir and naloxegol is</p><p>contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS</strong></p></td></tr><tr><td style="vertical-align:top"><p>For the treatment of erectile dysfunction</p><p>Avanafil</p><p>Sildenafil</p><p>Tadalafil</p><p>Vardenafil</p></td><td style="vertical-align:top"><p>In an interaction study&nbsp;<sup>#</sup>, a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with Darunavir and low dose ritonavir.</p></td><td style="vertical-align:top"><p>The combination of avanafil and boosted Darunavir is contraindicated</p><p>Concomitant use of other PDE-5 inhibitors for the treatment of erectile dysfunction with boosted Darunavir should be done with caution. If concomitant use of boosted Darunavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>For the treatment of pulmonary arterial hypertension</p><p>Sildenafil</p><p>Tadalafil</p></td><td style="vertical-align:top"><p>Not studied. Concomitant use of sildenafil or tadalafil for the treatment of pulmonary arterial hypertension and boosted Darunavir may increase plasma concentrations of sildenafil or tadalafil.</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with boosted Darunavir has not been established. There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope). Therefore, co-administration of boosted Darunavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated.</p><p>Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with boosted Darunavir is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PROTON PUMP INHIBITORS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole</p><p>20 mg once daily</p></td><td style="vertical-align:top"><p><sup>#</sup>Darunavir AUC &harr;</p><p><sup>#</sup>Darunavir C<sub>min</sub>&nbsp;&harr;</p><p><sup>#</sup>Darunavir C<sub>max</sub>&nbsp;&harr;</p></td><td style="vertical-align:top"><p>Boosted Darunavir can be co-administered with proton pump inhibitors without dose adjustments.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>SEDATIVES/HYPNOTICS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Buspirone</p><p>Clorazepate</p><p>Diazepam</p><p>Estazolam</p><p>Flurazepam</p><p>Midazolam (parenteral)</p><p>Zoldipem</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Midazolam (oral)</p><p>Triazolam</p></td><td style="vertical-align:top"><p>Not studied. Sedative/hypnotics are extensively metabolised by CYP3A. Co-administration with boosted Darunavir may cause a large increase in the concentration of these medicines.</p><p>If parenteral midazolam is co-administered with boosted Darunavir it may cause a large increase in the concentration of this benzodiazepine. Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.</p></td><td style="vertical-align:top"><p>Clinical monitoring is recommended when co-administering boosted Darunavir with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered.</p><p>If parenteral midazolam is co-administered with boosted Darunavir it should be done in an intensive care unit (ICU) or similar setting, which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dose adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.</p><p>Boosted Darunavir with triazolam or oral midazolam is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>TREATMENT FOR PREMATURE EJACULATION</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dapoxetime</p></td><td style="vertical-align:top"><p>Not studied</p></td><td style="vertical-align:top"><p>Co-administration of boosted</p><p>Darunavir with dapoxetine is</p><p>contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>UROLOGICAL DRUGS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fesoterodine</p><p>Solifenacin</p></td><td style="vertical-align:top"><p>Not studied</p></td><td style="vertical-align:top"><p>Use with caution. Monitor for</p><p>fesoterodine or solifenacin adverse</p><p>reactions, dose reduction of</p><p>fesoterodine or solifenacin may be</p><p>necessary.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>#</sup></strong><strong>&nbsp;</strong>studies have been performed at lower than recommended doses of Darunavir or with a different dosing regimen.</p><p><sup>&dagger;&nbsp;</sup>The efficacy and safety of the use of Darunavir with 100 mg ritonavir and any other HIV PI (e.g. (fos) amprenavir, nelfinavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.</p><p><sup>&Dagger;&nbsp;</sup>Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account.</p><p>&nbsp;</p><p>There are no adequate and well controlled studies on pregnancy outcome with Darunavir in pregnant women. Studies in animals do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.</p><p>&nbsp;</p><p>Darunavir co-administered with low dose ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.</p><p>&nbsp;</p><p>Treatment with Darunavir/cobicistat 800/150 mg during pregnancy results in low Darunavir exposure. which may be associated with an increased risk of treatment failure and an increased risk of HIV transmission to the child. Therapy with Darunavir /cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir /cobicistat should be switched to an alternative regimen.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether Darunavir is excreted in human milk. Studies in rats have demonstrated that Darunavir is excreted in milk and at high levels (1,000 mg/kg/day) resulted in toxicity. Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving Darunavir.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of Darunavir on fertility are available. There was no effect on mating or fertility with Darunavir treatment in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Darunavir in combination with cobicistat or ritonavir has no or negligible influence on the ability to drive and use machines. However, dizziness has been reported in some patients during treatment with regimens containing Darunavir co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>During the clinical development program (N=2,613 treatment-experienced subjects who initiated therapy with Darunavir /ritonavir 600/100 mg twice daily), 51.3% of subjects experienced at least one adverse reaction. The total mean treatment duration for subjects was 95.3 weeks. The most frequent adverse reactions reported in clinical trials and as spontaneous reports are diarrhoea, nausea, rash, headache and vomiting. The most frequent serious reactions are acute renal failure, myocardial infarction, immune reconstitution inflammatory syndrome, thrombocytopenia, osteonecrosis, diarrhoea, hepatitis and pyrexia.</p><p>&nbsp;</p><p>In the 96 week analysis, the safety profile of Darunavir /ritonavir 800/100 mg once daily in treatment na&iuml;ve subjects was similar to that seen with Darunavir /ritonavir 600/100 mg twice daily in treatment-experienced subjects except for nausea which was observed more frequently in treatment-na&iuml;ve subjects. This was driven by mild intensity nausea. No new safety findings were identified in the 192 week analysis of the treatment-na&iuml;ve subjects in which the mean treatment duration of Darunavir /ritonavir 800/100 mg once daily was 162.5 weeks.</p><p>&nbsp;</p><p>During the Phase III clinical trial GS-US-216-130 with Darunavir/cobicistat (N=313 treatment-na&iuml;ve and treatment experienced subjects), 66.5% of subjects experienced at least one adverse reaction. The mean treatment duration was 58.4 weeks. The most frequent adverse reactions reported were diarrhoea (28%), nausea (23%), and rash (16%).Serious adverse reactions are diabetes mellitus, (drug) hypersensitivity, immune reconstitution inflammatory syndrome, rash and vomiting.</p><p>&nbsp;</p><p>For information on cobicistat, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed by system organ class (SOC) and frequency category. Within each frequency category,adverse reactions are presented in order of decreasing seriousness. Frequency categories are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p><em>Adverse reactions observed with Darunavir/ritonavir in clinical trials and post-marketing</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td style="vertical-align:top"><p>MedDRA system organ class</p><p>Frequency category</p></td><td style="vertical-align:top"><p>Adverse reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Infections and infestations</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>herpes simplex</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>thrombocytopenia, neutropenia, anaemia, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>increased eosinophil count</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>immune reconstitution inflammatory syndrome, (drug) hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Endocrine disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>hypothyroidism, increased blood thyroid stimulating hormone</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>depression, disorientation, anxiety, sleep disorder, abnormal dreams, nightmare, decreased libido</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>confusional state, altered mood, restlessness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>headache, peripheral neuropathy, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>lethargy, paraesthesia, hypoaesthesia, dysgeusia, disturbance in attention, memory impairment, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>syncope, convulsion, ageusia, sleep phase rhythm disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>conjunctival hyperaemia, dry eye</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>visual disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>myocardial infarction, angina pectoris, prolonged electrocardiogram QT, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>acute myocardial infarction, sinus bradycardia, palpitations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>hypertension, flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>dyspnoea, cough, epistaxis, throat irritation</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>rhinorrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>pancreatitis, gastritis, gastroesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>stomatitis, haematemesis, cheilitis, dry lip, coated tongue</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>increased alanine aminotransferase</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>DRESS, Stevens-Johnson syndrome, erythema multiforme, dermatitis, seborrhoeic dermatitis, skin lesion, xeroderma</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, acute generalised exanthematous pustulosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>musculoskeletal stiffness, arthritis, joint stiffness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>decreased creatinine renal clearance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>erectile dysfunction, gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>pyrexia, chest pain, peripheral oedema, malaise, feeling hot, irritability, pain</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>chills, abnormal feeling, xerosis</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Adverse reactions observed with Darunavir/cobicistat in adult patients</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:667px"><tbody><tr><td style="vertical-align:top"><p>MedDRA system organ class</p><p>Frequency category</p></td><td style="vertical-align:top"><p>Adverse reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>(drug) hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>immune reconstitution inflammatory syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>anorexia, diabetes mellitus, hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>abnormal dreams</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>diarrhoea, nausea</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, pancreatic enzymes increased</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>pancreatitis acute</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>hepatic enzyme increased</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>hepatitis*, cytolytic hepatitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalised rash, and allergic dermatitis)</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>angioedema, pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>drug reaction with eosinophilia and systemic symptoms*, Stevens-Johnson syndrome*</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis*, acute generalised exanthematous pustulosis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>myalgia</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>osteonecrosis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>gynaecomastia*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>increased blood creatinine</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* these adverse drug reactions have not been reported in clinical trial experience with Darunavir/cobicistat but have been noted with Darunavir/ritonavir treatment and could be expected with Darunavir/cobicistat too.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Rash</em></p><p>In clinical trials, rash was mostly mild to moderate, often occurring within the first four weeks of treatment and resolving with continued dosing. In cases of severe skin reaction see the warning in section 4.4. In a single arm trial investigating Darunavir 800 mg once daily in combination with cobicistat 150 mg once daily and other antiretrovirals 2.2% of patients discontinued treatment due to rash.</p><p>&nbsp;</p><p>During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective of causality, was more commonly observed with regimens containing Darunavir /ritonavir + raltegravir compared to those containing Darunavir /ritonavir without raltegravir or raltegravir without Darunavir /ritonavir. Rash considered by the investigator to be drug-related occurred at similar rates. The exposure-adjusted rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively. The rashes</p><p>observed in clinical studies were mild to moderate in severity and did not result in discontinuation of therapy.</p><p><em>Metabolic parameters</em></p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy.</p><p>&nbsp;</p><p><em>Musculosk eletal abnormalities</em></p><p>Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have been reported with the use of protease inhibitors,particularly in combination with NRTIs.</p><p>&nbsp;</p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown.</p><p><em>&nbsp;</em></p><p><em>Immune reconstitution inflammatory syndrome</em></p><p>In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&#39; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><em>Bleeding in haemophiliac patients</em></p><p>There have been reports of increased spontaneous bleeding in haemophiliac patients receiving antiretroviral protease inhibitors.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety assessment in paediatric patients is based on the 48-week analysis of safety data from three Phase II trials.The following patient populations were evaluated.</p><p>&nbsp;</p><p>&bull; 80 ART-experienced HIV-1 infected paediatric patients aged from 6 to 17 years and weighing at least 20 kg who received Darunavir tablets with low dose ritonavir twice daily in combination with other antiretroviral agents.</p><p>&nbsp;</p><p>&bull; 21 ART-experienced HIV-1 infected paediatric patients aged from 3 to &lt; 6 years and weighing 10 kg to &lt; 20 kg (16 participants from 15 kg to &lt; 20 kg) who received Darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents.</p><p>&nbsp;</p><p>&bull; 12 ART-na&iuml;ve HIV-1 infected paediatric patients aged from 12 to 17 years and weighing at least 40 kg who received Darunavir tablets with low dose ritonavir once daily in combination with other antiretroviral agents.</p><p>&nbsp;</p><p>Overall, the safety profile in these paediatric patients was similar to that observed in the adult population.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p><em>Patients co-infected with hepatitis B and/or hepatitis C virus</em></p><p>Among 1,968 treatment-experienced patients receiving Darunavir co-administered with ritonavir 600/100 mg twice daily,236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Center (NPC)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human experience of acute overdose with Darunavir co-administered with cobicistat or low dose ritonavir is limited.Single doses up to 3,200 mg of Darunavir as oral solution alone and up to 1,600 mg of the tablet formulation of Darunavir in combination with ritonavir have been administered to healthy volunteers without untoward symptomatic effects.</p><p>&nbsp;</p><p>There is no specific antidote for overdose with Darunavir. Treatment of overdose with Darunavir consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Since Darunavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitors.ATC code: J05AE10.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease (KD of 4.5 x 10-12M). It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles.</p><p>&nbsp;</p><p><u>Antiviral activity </u><em><u>in vitro</u></em></p><p>Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/ml). Darunavir demonstrates antiviral activity <em>in vitro</em> against a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50 values ranging from &lt; 0.1 to 4.3 nM.</p><p>&nbsp;</p><p>These EC50 values are well below the 50% cellular toxicity concentration range of 87 &mu;M to &gt; 100 &mu;M.</p><p>&nbsp;</p><p><u>Resistance</u></p><p><em>In vitro </em>selection of Darunavir-resistant virus from wild type HIV-1 was lengthy (&gt; 3 years). The selected viruses were unable to grow in the presence of Darunavir concentrations above 400 nM. Viruses selected in these conditions and showing decreased susceptibility to Darunavir (range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene. The decreased susceptibility to Darunavir of the emerging viruses in the selection experiment could not be explained by the emergence of these protease mutations.</p><p>&nbsp;</p><p>&nbsp;</p><p>The clinical trial data from ART-experienced patients (<em>TITAN </em>trial and the pooled analysis of the <em>POWER </em>1, 2 and 3 and <em>DUET </em>1 and 2 trials) showed that virologic response to Darunavir co-administered with low dose ritonavir was decreased when 3 or more Darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) were present at baseline or when these mutations developed during treatment.</p><p>&nbsp;</p><p>Increasing baseline Darunavir fold change in EC50 (FC) was associated with decreasing virologic response. A lower and upper clinical cut-off of 10 and 40 were identified. Isolates with baseline FC &le; 10 are susceptible; isolates with FC &gt; 10 to 40 have decreased susceptibility; isolates with FC &gt; 40 are resistant.</p><p>&nbsp;</p><p>Viruses isolated from patients on Darunavir /ritonavir 600/100 mg twice daily experiencing virologic failure by rebound that were susceptible to tipranavir at baseline remained susceptible to tipranavir after treatment in the vast majority of cases.</p><p>&nbsp;</p><p>The lowest rates of developing resistant HIV virus are observed in ART-na&iuml;ve patients who are treated for the first time with Darunavir in combination with other ART.</p><p>&nbsp;</p><p>The table below shows the development of HIV-1 protease mutations and loss of susceptibility to PIs in virologic failures at endpoint in the <em>ARTEMIS</em>, <em>ODIN </em>and <em>TITAN </em>trials.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>ARTEMIS</p><p>Week 192</p></td><td colspan="2" style="vertical-align:top"><p>ODIN</p><p>Week 48</p></td><td style="vertical-align:top"><p>TITAN</p><p>Week 48</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>800/100 mg</p><p>once daily</p><p>N=343</p></td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>800/100 mg</p><p>once daily</p><p>N=294</p></td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>600/100 mg</p><p>twice daily</p><p>N=296</p></td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>600/100 mg</p><p>twice daily</p><p>N=298</p></td></tr><tr><td style="vertical-align:top"><p>Total number of virologic failuresa, n (%)</p></td><td style="vertical-align:top"><p>55 (16.0%)</p></td><td style="vertical-align:top"><p>65 (22.1%)</p></td><td style="vertical-align:top"><p>54 (18.2%)</p></td><td style="vertical-align:top"><p>31 (10.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Rebounders</p></td><td style="vertical-align:top"><p>39 (11.4%)</p></td><td style="vertical-align:top"><p>11 (3.7%)</p></td><td style="vertical-align:top"><p>11 (3.7%)</p></td><td style="vertical-align:top"><p>16 (5.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Never suppressed subjects</p></td><td style="vertical-align:top"><p>16 (4.7%)</p></td><td style="vertical-align:top"><p>54 (18.4%)</p></td><td style="vertical-align:top"><p>43 (14.5%)</p></td><td style="vertical-align:top"><p>15 (5.0%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Number of subjects with virologic failure and paired baseline/endpoint genotypes, developing mutationsb&nbsp;at endpoint, n/N</p></td></tr><tr><td style="vertical-align:top"><p>Primary (major) PI mutations</p></td><td style="vertical-align:top"><p>0/43</p></td><td style="vertical-align:top"><p>1/60</p></td><td style="vertical-align:top"><p>0/42</p></td><td style="vertical-align:top"><p>6/28</p></td></tr><tr><td style="vertical-align:top"><p>PI RAMs</p></td><td style="vertical-align:top"><p>4/43</p></td><td style="vertical-align:top"><p>7/60</p></td><td style="vertical-align:top"><p>4/42</p></td><td style="vertical-align:top"><p>10/28</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Number of subjects with virologic failure and paired baseline/endpoint phenotypes, showing loss of susceptibility to PIs at endpoint compared to baseline, n/N</p></td></tr><tr><td style="vertical-align:top"><p>PI</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Darunavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>1/58</p></td><td style="vertical-align:top"><p>0/41</p></td><td style="vertical-align:top"><p>3/26</p></td></tr><tr><td style="vertical-align:top"><p>amprenavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>1/58</p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>0/22</p></td></tr><tr><td style="vertical-align:top"><p>atazanavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>2/56</p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>0/22</p></td></tr><tr><td style="vertical-align:top"><p>indinavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>2/57</p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>1/24</p></td></tr><tr><td style="vertical-align:top"><p>lopinavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>1/58</p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>0/23</p></td></tr><tr><td style="vertical-align:top"><p>saquinavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>0/56</p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>0/22</p></td></tr><tr><td style="vertical-align:top"><p>tipranavir</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>0/58</p></td><td style="vertical-align:top"><p>0/41</p></td><td style="vertical-align:top"><p>1/25</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>a&nbsp;TLOVR non-VF censored algorithm based on HIV-1 RNA &lt; 50 copies/ml, except for&nbsp;TITAN&nbsp;(HIV-1 RNA &lt; 400 copies/ml)</p><p>b&nbsp;IAS-USA lists</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Low rates of developing resistant HIV-1 virus were observed in ART-na&iuml;ve patients who are treated for the first time with Darunavir/cobicistat once daily in combination with other ART, and in ART-experienced patients with no Darunavir RAMs receiving Darunavir/cobicistat in combination with other ART. The table below shows the development of HIV-1 protease mutations and resistance to PIs in virologic failures at endpoint in the GS-US-216-130 trial.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p>GS-US-216-130</p><p>Week 48</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Treatment-na&iuml;ve</p><p>Darunavir/cobicistat 800/150 mg</p><p>once daily</p><p>N=295</p></td><td style="vertical-align:top"><p>Treatment-experienced</p><p>Darunavir/cobicistat 800/150 mg</p><p>once daily</p><p>N=18</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Number of subjects with virologic failurea&nbsp;and genotype data that develop mutationsb&nbsp;at endpoint, n/N</p></td></tr><tr><td style="vertical-align:top"><p>Primary (major) PI mutations</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>1/7</p></td></tr><tr><td style="vertical-align:top"><p>PI RAMs</p></td><td style="vertical-align:top"><p>2/8</p></td><td style="vertical-align:top"><p>1/7</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Number of subjects with virologic failurea&nbsp;and phenotype data that show resistance to PIs at endpointc, n/N</p></td></tr><tr><td style="vertical-align:top"><p>HIV PI</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Darunavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>amprenavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>atazanavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>indinavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>lopinavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>saquinavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td style="vertical-align:top"><p>tipranavir</p></td><td style="vertical-align:top"><p>0/8</p></td><td style="vertical-align:top"><p>0/7</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a&nbsp;Virologic failures were defined as: never suppressed: confirmed HIV-1 RNA &lt; 1 log10&nbsp;reduction from baseline and &ge; 50 copies/ml at the week-8; rebound: HIV-1 RNA &lt; 50 copies/ml followed by confirmed HIV-1 RNA to &ge; 400 copies/ml or confirmed &gt; 1 log10&nbsp;HIV-1 RNA increase from the nadir; discontinuations with HIV-1 RNA &ge; 400 copies/ml at last visit</p><p>b&nbsp;IAS-USA lists</p><p>c&nbsp;In GS-US216-130 baseline phenotype was not available</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Cross-resistance</u></p><p>Darunavir FC was less than 10 for 90% of 3,309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that viruses resistant to most PIs remain susceptible to Darunavir.</p><p>In the virologic failures of the <em>ARTEMIS </em>trial no cross-resistance with other PIs was observed.</p><p>&nbsp;</p><p>In the virologic failures of the GS-US-216-130 trial no cross-resistance with other HIV PIs was observed.</p><p>&nbsp;</p><p><u>Clinical results</u></p><p>The pharmacokinetic enhancing effect of cobicistat on Darunavir was evaluated in a Phase I study in healthy subjects that were administered Darunavir 800 mg with either cobicistat at 150 mg or ritonavir at 100 mg once daily. The steadystate pharmacokinetic parameters of Darunavir were comparable when boosted with cobicistat versus ritonavir. For information on cobicistat, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p><u>Adult patients</u></p><p>&nbsp;</p><p><em><u>Efficacy of Darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-na&iuml;ve and ART experienced patients</u></em></p><p>&nbsp;</p><p>GS-US-216-130 is a single arm, open-label, Phase III trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of Darunavir with cobicistat in 313 HIV-1 infected adult patients (295 treatment-na&iuml;ve and 18 treatmentexperienced).These patients received Darunavir 800 mg once daily in combination with cobicistat 150 mg once daily with an investigator selected background regimen consisting of 2 active NRTIs.</p><p>HIV-1 infected patients who were eligible for this trial had a screening genotype showing no Darunavir RAMs and plasma HIV-1 RNA &ge; 1,000 copies/ml.</p><p>The table below shows the efficacy data of the 48 week analyses from the GS-US-216-130 trial:</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>GS-US-216-130</p></td></tr><tr><td><p>Outcomes at Week 48</p></td><td style="vertical-align:top"><p>Treatment-na&iuml;ve</p><p>Darunavir/cobicistat 800/150 mg once daily</p><p>+ OBR</p><p>N=295</p></td><td style="vertical-align:top"><p>Treatment-experienced</p><p>Darunavir/cobicistat 800/150 mg once daily</p><p>+ OBR</p><p>N=18</p></td><td style="vertical-align:top"><p>All subjects</p><p>Darunavir/cobicistat 800/150 mg once daily</p><p>+ OBR</p><p>N=313</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt; 50 copies/mla</p></td><td style="vertical-align:top"><p>245 (83.1%)</p></td><td style="vertical-align:top"><p>8 (44.4%)</p></td><td style="vertical-align:top"><p>253 (80.8%)</p></td></tr><tr><td style="vertical-align:top"><p>mean HIV-1 RNA log change from baseline (log10&nbsp;copies/ml)</p></td><td style="vertical-align:top"><p>-3.01</p></td><td style="vertical-align:top"><p>-2.39</p></td><td style="vertical-align:top"><p>-2.97</p></td></tr><tr><td style="vertical-align:top"><p>CD4+ cell count mean change from baselineb</p></td><td style="vertical-align:top"><p>+174</p></td><td style="vertical-align:top"><p>+102</p></td><td style="vertical-align:top"><p>+170</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a&nbsp;Imputations according to the TLOVR algorithm</p><p>b&nbsp;Last Observation Carried Forward imputation</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Efficacy of </u></em><u>Darunavir</u><em><u> 800 mg once daily co</u></em><u>-<em>administered with 100 mg ritonavir once daily in ART-na&iuml;ve patients</em></u></p><p>&nbsp;</p><p>The evidence of efficacy of Darunavir /ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial <em>ARTEMIS </em>in antiretroviral treatment-na&iuml;ve HIV-1 infected patients comparing Darunavir /ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen). Both arms used a fixed background regimen consisting of tenofovir disoproxil fumarate 300 mg once daily and emtricitabine 200 mg once daily.</p><p>&nbsp;</p><p>The table below shows the efficacy data of the 48 week and 96 week analyses from the <em>ARTEMIS </em>trial:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td colspan="7" style="vertical-align:top"><p>ARTEMIS</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>Week 48a</p></td><td colspan="3" style="vertical-align:top"><p>Week 96b</p></td></tr><tr><td style="vertical-align:top"><p>Outcomes</p></td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>800/100 mg once daily</p><p>N=343</p></td><td style="vertical-align:top"><p>Lopinavir/ ritonavir</p><p>800/200 mg per day</p><p>N=346</p></td><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI of difference)</p></td><td style="vertical-align:top"><p>Darunavir / ritonavir</p><p>800/100 mg once daily</p><p>N=343</p></td><td style="vertical-align:top"><p>Lopinavir/ ritonavir</p><p>800/200 mg per day</p><p>N=346</p></td><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI of difference)</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt; 50 copies/mlc</p><p>All patients</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>83.7%</p><p>(287)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>78.3%</p><p>(271)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.3%</p><p>(-0.5; 11.2)d</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>79.0%</p><p>(271)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>70.8%</p><p>(245)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.2%</p><p>(1.7; 14.7)d</p></td></tr><tr><td style="vertical-align:top"><p>With baseline HIV-RNA &lt; 100,000</p></td><td style="vertical-align:top"><p>85.8%</p><p>(194/226)</p></td><td style="vertical-align:top"><p>84.5%</p><p>(191/226)</p></td><td style="vertical-align:top"><p>1.3%</p><p>(-5.2; 7.9)d</p></td><td style="vertical-align:top"><p>80.5%</p><p>(182/226)</p></td><td style="vertical-align:top"><p>75.2%</p><p>(170/226)</p></td><td style="vertical-align:top"><p>5.3%</p><p>(-2.3; 13.0)d</p></td></tr><tr><td style="vertical-align:top"><p>With baseline HIV-RNA &ge; 100,000</p></td><td style="vertical-align:top"><p>79.5%</p><p>(93/117)</p></td><td style="vertical-align:top"><p>66.7%</p><p>(80/120)</p></td><td style="vertical-align:top"><p>12.8%</p><p>(1.6; 24.1)d</p></td><td style="vertical-align:top"><p>76.1%</p><p>(89/117)</p></td><td style="vertical-align:top"><p>62.5%</p><p>(75/120)</p></td><td style="vertical-align:top"><p>13.6%</p><p>(1.9; 25.3)d</p></td></tr><tr><td style="vertical-align:top"><p>With baseline CD4+ cell count &lt; 200</p></td><td style="vertical-align:top"><p>79.4%</p><p>(112/141)</p></td><td style="vertical-align:top"><p>70.3%</p><p>(104/148)</p></td><td style="vertical-align:top"><p>9.2%</p><p>(-0.8; 19.2)d</p></td><td style="vertical-align:top"><p>78.7%</p><p>(111/141)</p></td><td style="vertical-align:top"><p>64.9%</p><p>(96/148)</p></td><td style="vertical-align:top"><p>13.9%</p><p>(3.5; 24.2)d</p></td></tr><tr><td style="vertical-align:top"><p>With baseline CD4+ cell count &ge; 200</p></td><td style="vertical-align:top"><p>86.6%</p><p>(175/202)</p></td><td style="vertical-align:top"><p>84.3%</p><p>(167/198)</p></td><td style="vertical-align:top"><p>2.3%</p><p>(-4.6; 9.2)d</p></td><td style="vertical-align:top"><p>79.2%</p><p>(160/202)</p></td><td style="vertical-align:top"><p>75.3%</p><p>(149/198)</p></td><td style="vertical-align:top"><p>4.0%</p><p>(-4.3; 12.2)d</p></td></tr><tr><td style="vertical-align:top"><p>median CD4+ cell count change from baseline (x 106/l)e</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>188</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="7" style="vertical-align:top"><p>a&nbsp;Data based on analyses at week 48</p><p>b&nbsp;Data based on analyses at week 96</p><p>c&nbsp;Imputations according to the TLOVR algorithm</p><p>d&nbsp;Based on normal approximation to the difference in % response</p><p>e&nbsp;Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0</p></td></tr></tbody></table><p>&nbsp;</p><p>Non-inferiority in virologic response to the Darunavir /ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level &lt; 50 copies/ml, was demonstrated (at the pre-defined 12% non-inferiority margin) for both Intent-To-Treat (ITT) and On Protocol (OP) populations in the 48 week analysis. These results were confirmed in the analyses of data at 96 weeks of treatment in the <em>ARTEMIS </em>trial. These results were sustained up to 192 weeks of treatment in the ARTEMIS trial.</p><p>&nbsp;</p><p><em><u>Efficacy </u></em><em>of </em>Darunavir<em><u> 800 mg once daily co</u></em><u>-</u><em><u>administered with 100 mg ritonavir once daily in ART-experienced patients</u></em></p><p>&nbsp;</p><p><em>ODIN </em>is a Phase III, randomised, open-label trial comparing Darunavir /ritonavir 800/100 mg once daily versus Darunavir /ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no Darunavir RAMs (i.e. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA &gt; 1,000 copies/ml. Efficacy analysis is based on 48 weeks of treatment (see table below).Both arms used an optimised background regimen (OBR) of &ge; 2 NRTIs.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td colspan="4" style="vertical-align:top"><p>ODIN</p></td></tr><tr><td style="vertical-align:top"><p>Outcomes</p></td><td style="vertical-align:top"><p>Darunavir /ritonavir 800/100 mg once daily + OBR</p><p>N=294</p></td><td style="vertical-align:top"><p>Darunavir /ritonavir 600/100 mg twice daily + OBR</p><p>N=296</p></td><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI of difference)</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt; 50 copies/mla</p></td><td style="vertical-align:top"><p>72.1% (212)</p></td><td style="vertical-align:top"><p>70.9% (210)</p></td><td style="vertical-align:top"><p>1.2% (-6.1; 8.5)b</p></td></tr><tr><td style="vertical-align:top"><p>With Baseline HIV-1 RNA (copies/ml)</p><p>&lt; 100,000</p><p>&ge; 100,000</p></td><td style="vertical-align:bottom"><p>77.6% (198/255)</p><p>35.9% (14/39)</p></td><td style="vertical-align:bottom"><p>73.2% (194/265)</p><p>51.6% (16/31)</p></td><td style="vertical-align:bottom"><p>4.4% (-3.0; 11.9)</p><p>-15.7% (-39.2; 7.7)</p></td></tr><tr><td style="vertical-align:top"><p>With Baseline CD4+ cell count (x 106/l)</p><p>&ge; 100</p><p>&lt; 100</p></td><td style="vertical-align:bottom"><p>75.1% (184/245)</p><p>57.1% (28/49)</p></td><td style="vertical-align:bottom"><p>72.5% (187/258)</p><p>60.5% (23/38)</p></td><td style="vertical-align:bottom"><p>2.6% (-5.1; 10.3)</p><p>-3.4% (-24.5; 17.8)</p></td></tr><tr><td style="vertical-align:top"><p>With HIV-1 clade</p><p>Type B</p><p>Type AE</p><p>Type C</p><p>Otherc</p></td><td style="vertical-align:bottom"><p>70.4% (126/179)</p><p>90.5% (38/42)</p><p>72.7% (32/44)</p><p>55.2% (16/29)</p></td><td style="vertical-align:bottom"><p>64.3% (128/199)</p><p>91.2% (31/34)</p><p>78.8% (26/33)</p><p>83.3% (25/30)</p></td><td style="vertical-align:bottom"><p>6.1% (-3.4; 15.6)</p><p>-0.7% (-14.0; 12.6)</p><p>-6.1% (-2.6; 13.7)</p><p>-28.2% (-51.0; -5.3)</p></td></tr><tr><td style="vertical-align:top"><p>mean CD4+ cell count change from baseline</p><p>(x 106/l)e</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>112</p></td><td style="vertical-align:top"><p>-5d&nbsp;(-25; 16)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a&nbsp;Imputations according to the TLOVR algorithm</p><p>b&nbsp;Based on a normal approximation of the difference in % response</p><p>c&nbsp;Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX</p><p>d&nbsp;Difference in means</p><p>e&nbsp;Last Observation Carried Forward imputation</p></td></tr></tbody></table><p>&nbsp;</p><p>At 48 weeks, virologic response, defined as the percentage of patients with plasma HIV-1 RNA level &lt; 50 copies/ml, with Darunavir /ritonavir 800/100 mg once daily treatment was demonstrated to be non-inferior (at the pre-defined 12% noninferiority margin) compared to Darunavir /ritonavir 600/100 mg twice daily for both ITT and OP populations.</p><p>Darunavir /ritonavir 800/100 mg once daily in ART-experienced patients should not be used in patients with one or more Darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA &ge; 100,000 copies/ml or CD4+ cell count &lt; 100 cells x 106/l. Limited data is available in patients with HIV-1 clades other than B.</p><p>&nbsp;</p><p><u>Paediatric patients</u></p><p><em>ART-na&iuml;ve paediatric patients from the age of 12 years to &lt; 18 years, and weighing at least 40 kg</em></p><p><em>&nbsp;</em></p><p><em>DIONE </em>is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of Darunavir with low dose ritonavir in 12 ART-na&iuml;ve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg. These patients received Darunavir /ritonavir 800/100 mg once daily in combination with other antiretroviral agents. Virologic response was defined as a decrease in plasma HIV-1 RNA viral load of at least 1.0 log10 versus baseline.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:677px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>DIONE</p></td></tr><tr><td><p>Outcomes at week 48</p></td><td style="vertical-align:top"><p>Darunavir /ritonavir</p><p>N=12</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt; 50 copies/mla</p></td><td style="vertical-align:top"><p>83.3% (10)</p></td></tr><tr><td style="vertical-align:top"><p>CD4+ percent change from baselineb</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>CD4+ cell count mean change from baselineb</p></td><td style="vertical-align:top"><p>221</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 1.0 log10&nbsp;decrease from baseline in plasma viral load</p></td><td style="vertical-align:top"><p>100%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>a&nbsp;Imputations according to the TLOVR algorithm.</p><p>b&nbsp;Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0.</p></td></tr></tbody></table><p>&nbsp;</p><p>For additional clinical study results in ART-experienced adults and paediatric patients, refer to the Summary of Product Characteristics for Darunavir 75 mg, 150 mg, 300 mg or 600 mg tablets and 100 mg/ml oral suspension.</p><p>&nbsp;</p><p><em>Pregnancy and postpartum</em></p><p>Darunavir/ritonavir (600/100 mg twice daily or 800/100 mg once daily) in combination with a background regimen was<em> </em>evaluated in a clinical trial of 36 pregnant women (18 in each arm) during the second and third trimesters, and<em> </em>postpartum. Virologic response was preserved throughout the study period in both arms. No mother to child<em> </em>transmission occurred in the infants born to the 31 subjects who stayed on the antiretroviral treatment through delivery.There were no new clinically relevant safety findings compared with the known safety profile of Darunavir/ritonavir in HIV-1<em> </em>infected adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of Darunavir, co-administered with cobicistat or ritonavir, have been evaluated in healthy adult volunteers and in HIV-1 infected patients. Exposure to Darunavir was higher in HIV-1 infected patients than in healthy subjects. The increased exposure to Darunavir in HIV-1 infected patients compared to healthy subjects may be explained by the higher concentrations of &alpha;1-acid glycoprotein (AAG) in HIV-1 infected patients, resulting in higher Darunavir binding to plasma AAG and, therefore, higher plasma concentrations.</p><p>&nbsp;</p><p>Darunavir is primarily metabolised by CYP3A. Cobicistat and ritonavir inhibit CYP3A, thereby increasing the plasma concentrations of Darunavir considerably.</p><p>&nbsp;</p><p>For information on cobicistat pharmacokinetic properties, consult the cobicistat Summary of Product Characteristics.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Darunavir was rapidly absorbed following oral administration. Maximum plasma concentration of Darunavir in the presence of low dose ritonavir is generally achieved within 2.5-4.0 hours.</p><p>&nbsp;</p><p>The absolute oral bioavailability of a single 600 mg dose of Darunavir alone was approximately 37% and increased to approximately 82% in the presence of 100 mg twice daily ritonavir. The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of Darunavir when a single dose of 600 mg Darunavir was given orally in combination with ritonavir at 100 mg twice daily.</p><p>When administered without food, the relative bioavailability of Darunavir in the presence of cobicistat or low dose ritonavir is lower as compared to intake with food. Therefore, Darunavir tablets should be taken with cobicistat or ritonavir and with food. The type of food does not affect exposure to Darunavir.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Darunavir is approximately 95% bound to plasma protein. Darunavir binds primarily to plasma &alpha;1-acid glycoprotein.</p><p>&nbsp;</p><p>Following intravenous administration, the volume of distribution of Darunavir alone was 88.1 &plusmn; 59.0 l (Mean &plusmn; SD) and increased to 131 &plusmn; 49.9 l (Mean &plusmn; SD) in the presence of 100 mg twice-daily ritonavir.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro </em>experiments with human liver microsomes (HLMs) indicate that Darunavir primarily undergoes oxidative metabolism. Darunavir is extensively metabolised by the hepatic CYP system and almost exclusively by isozyme CYP3A4. A 14C-Darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg Darunavir with ritonavir dose was due to the parent active substance. At least 3 oxidative metabolites of Darunavir have been identified in humans; all showed activity that was at least 10-fold less than the activity of Darunavir against wild type HIV.</p><p><u>Elimination</u></p><p>After a 400/100 mg 14C-Darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of 14CDarunavir could be retrieved in faeces and urine, respectively.</p><p>&nbsp;</p><p>&nbsp;Unchanged Darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively. The terminal elimination half-life of Darunavir was approximately 15 hours when combined with ritonavir.</p><p>&nbsp;</p><p>The intravenous clearance of Darunavir alone (150 mg) and in the presence of low dose ritonavir was 32.8 l/h and 5.9 l/h, respectively.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of Darunavir in combination with ritonavir taken twice daily in 74 treatment-experienced paediatric patients, aged 6 to 17 years and weighing at least 20 kg, showed that the administered weight-based doses of Darunavir /ritonavir resulted in Darunavir exposure comparable to that in adults receiving Darunavir /ritonavir 600/100 mg twice daily.</p><p>&nbsp;</p><p>The pharmacokinetics of Darunavir in combination with ritonavir taken twice daily in 14 treatment-experienced paediatric patients, aged 3 to &lt; 6 years and weighing at least 15 kg to &lt; 20 kg, showed that weight-based dosages resulted in Darunavir exposure that was comparable to that achieved in adults receiving Darunavir /ritonavir 600/100 mg twice daily.</p><p>&nbsp;</p><p>The pharmacokinetics of Darunavir in combination with ritonavir taken once daily in 12 ART-na&iuml;ve paediatric patients, aged 12 to &lt; 18 years and weighing at least 40 kg, showed that Darunavir /ritonavir 800/100 mg once daily results in Darunavir exposure that was comparable to that achieved in adults receiving Darunavir /ritonavir 800/100 mg once daily.Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to &lt; 18 years and weighing at least 40 kg without Darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 10<sup>6</sup>/I</p><p>* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</p><p>&nbsp;</p><p>The pharmacokinetics of Darunavir in combination with ritonavir taken once daily in 10 treatment-experienced paediatric patients, aged 3 to &lt; 6 years and weighing at least 14 kg to &lt; 20 kg, showed that weight-based dosages resulted in Darunavir exposure that was comparable to that achieved in adults receiving Darunavir /ritonavir 800/100 mg once daily. In addition, pharmacokinetic modeling and simulation of Darunavir exposures in paediatric patients across the ages of 3 to &lt; 18 years confirmed the Darunavir exposures as observed in the clinical studies and allowed the identification of weight-based Darunavir /ritonavir once daily dosing regimens for paediatric patients weighing at least 15 kg that are either ART-na&iuml;ve or treatment-experienced paediatric patients without DRV-RAMs* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count &ge; 100 cells x 106/l.</p><p>&nbsp;</p><p>* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</p><p>&nbsp;</p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>Population pharmacokinetic analysis in HIV infected patients showed that Darunavir pharmacokinetics are not considerably different in the age range (18 to 75 years) evaluated in HIV infected patients (n=12, age &ge; 65). However, only limited data were available in patients above the age of 65 year.</p><p>&nbsp;</p><p><em>Gender</em></p><p><em>&nbsp;</em></p><p>Population pharmacokinetic analysis showed a slightly higher Darunavir exposure (16.8%) in HIV infected females compared to males. This difference is not clinically relevant.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>Results from a mass balance study with 14C-Darunavir with ritonavir showed that approximately 7.7% of the administered dose of Darunavir is excreted in the urine unchanged.</p><p>&nbsp;</p><p>Although Darunavir has not been studied in patients with renal impairment, population pharmacokinetic analysis showed that the pharmacokinetics of Darunavir were not significantly affected in HIV infected patients with moderate renal impairment (CrCl between 30-60 ml/min, n=20).</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Darunavir is primarily metabolised and eliminated by the liver. In a multiple dose study with Darunavir co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of Darunavir in subjects with mild (Child-Pugh Class A, n=8) and moderate (Child-Pugh Class B, n=8) hepatic impairment were comparable with those in healthy subjects. However, unbound Darunavir concentrations were approximately 55% (Child-Pugh Class A) and 100% (Child-Pugh Class B) higher, respectively. The clinical relevance of this increase is unknown therefore, Darunavir should be used with caution. The effect of severe hepatic impairment on the pharmacokinetics of Darunavir has not been studied.</p><p>&nbsp;</p><p><em>Pregnancy and postpartum</em></p><p><em>&nbsp;</em></p><p>The exposure to total Darunavir and ritonavir after intake of Darunavir/ritonavir 600/100 mg twice daily and Darunavir/ritonavir 800/100 mg once daily as part of an antiretroviral regimen was generally lower during pregnancy compared with postpartum. However, for unbound (i.e. active) Darunavir, the pharmacokinetic parameters were less reduced during pregnancy compared to postpartum, due to an increase in the unbound fraction of Darunavir during pregnancy compared to postpartum.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Pharmacokinetic results of total Darunavir after administration of Darunavir/ritonavir at 600/100 mg twice daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pharmacokinetics of total Darunavir</strong></p><p><strong>(mean &plusmn; SD)</strong></p></td><td style="vertical-align:top"><p><strong>Second trimester of pregnancy</strong></p><p><strong>(n=12)a</strong></p></td><td style="vertical-align:top"><p><strong>Third trimester of pregnancy</strong></p><p><strong>(n=12)</strong></p></td><td style="vertical-align:top"><p><strong>Postpartum&nbsp;<br />(6-12 weeks)</strong></p><p><strong>(n=12)</strong></p></td></tr><tr><td><p>Cmax, ng/ml</p></td><td><p>4,668 &plusmn; 1,097</p></td><td><p>5,328 &plusmn; 1,631</p></td><td><p>6,659 &plusmn; 2,364</p></td></tr><tr><td style="vertical-align:bottom"><p>AUC12h, ng.h/ml</p></td><td style="vertical-align:bottom"><p>39,370 &plusmn; 9,597</p></td><td style="vertical-align:bottom"><p>45,880 &plusmn; 17,360</p></td><td style="vertical-align:bottom"><p>56,890 &plusmn; 26,340</p></td></tr><tr><td><p>Cmin, ng/ml</p></td><td><p>1,922 &plusmn; 825</p></td><td style="vertical-align:bottom"><p>2,661 &plusmn; 1,269</p></td><td><p>2,851 &plusmn; 2,216</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a n=11 for AUC12h</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Pharmacokinetic results of total Darunavir after administration of Darunavir/ritonavir at 600/100 mg twice daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pharmacokinetics of total Darunavir</strong></p><p><strong>(mean &plusmn; SD)</strong></p></td><td style="vertical-align:top"><p><strong>Second trimester of pregnancy</strong></p><p><strong>(n=17)</strong></p></td><td style="vertical-align:top"><p><strong>Third trimester of pregnancy</strong></p><p><strong>(n=15)</strong></p></td><td style="vertical-align:top"><p><strong>Postpartum&nbsp;<br />(6-12 weeks)</strong></p><p><strong>(n=16)</strong></p></td></tr><tr><td><p>Cmax, ng/ml</p></td><td><p>4,964 &plusmn; 1,505</p></td><td><p>5,132 &plusmn; 1,198</p></td><td><p>7,310 &plusmn; 1,704</p></td></tr><tr><td style="vertical-align:bottom"><p>AUC24h, ng.h/ml</p></td><td style="vertical-align:bottom"><p>62,282 &plusmn; 16,234</p></td><td style="vertical-align:bottom"><p>61,112 &plusmn; 13,790</p></td><td style="vertical-align:bottom"><p>92,116 &plusmn; 29,241</p></td></tr><tr><td><p>Cmin, ng/ml</p></td><td><p>1,248 &plusmn; 542</p></td><td style="vertical-align:bottom"><p>1,075 &plusmn; 594</p></td><td><p>1,473 &plusmn; 1,141</p></td></tr></tbody></table><p>&nbsp;</p><p>In women receiving Darunavir/ritonavir 600/100 mg twice daily during the second trimester of pregnancy, mean intraindividual values for total Darunavir Cmax, AUC12h and Cmin were 28%, 26% and 26% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total Darunavir Cmax, AUC12h and Cmin values were 18%, 16% lower and 2% higher, respectively, as compared with postpartum.</p><p>&nbsp;</p><p>In women receiving Darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intraindividual values for total Darunavir Cmax, AUC24h and Cmin were 33%, 31% and 30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total Darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum.</p><p>&nbsp;</p><p>Treatment with Darunavir/cobicistat 800/150 mg once daily during pregnancy results in low Darunavir exposure. In women receiving Darunavir/cobicistat during the second trimester of pregnancy, mean intra-individual values for total Darunavir Cmax, AUC24h and Cmin were 49%, 56% and 92% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total Darunavir Cmax, AUC24h and Cmin values were 37%, 50% and 89% lower, respectively, as compared with postpartum. The unbound fraction was also substantially reduced, including around 90% reductions of Cmin levels. The main cause of these low exposures is a marked reduction in cobicistat exposure as a consequence of pregnancy-associated enzyme induction (see below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Pharmacokinetic results of total Darunavir after administration of Darunavir/cobicistat 800/150 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy, and postpartum</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pharmacokinetics of total Darunavir</strong></p><p>(mean &plusmn; SD)</p></td><td style="vertical-align:top"><p><strong>Second trimester of pregnancy</strong></p><p><strong>(n=7)</strong></p></td><td style="vertical-align:top"><p><strong>Third trimester of pregnancy</strong></p><p><strong>(n=6)</strong></p></td><td style="vertical-align:top"><p><strong>Postpartum<br />(6 12 weeks)</strong></p><p><strong>(n=6)</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub>, ng/mL</p></td><td style="vertical-align:top"><p>4,340 &plusmn; 1,616</p></td><td style="vertical-align:top"><p>4,910 &plusmn; 970</p></td><td style="vertical-align:top"><p>7,918 &plusmn; 2,199</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>24h</sub>, ng.h/mL</p></td><td style="vertical-align:top"><p>47,293 &plusmn; 19,058</p></td><td style="vertical-align:top"><p>47,991 &plusmn; 9,879</p></td><td style="vertical-align:top"><p>99,613 &plusmn; 34,862</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>min</sub>, ng/mL</p></td><td style="vertical-align:top"><p>168 &plusmn; 149</p></td><td style="vertical-align:top"><p>184 &plusmn; 99</p></td><td style="vertical-align:top"><p>1,538 &plusmn; 1,344</p></td></tr></tbody></table><p>The exposure to cobicistat was lower during pregnancy, potentially leading to suboptimal boosting of Darunavir. During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%, 63%, and 83% lower, respectively, as compared with postpartum. During the third trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin, were 27%, 49%, and 83% lower, respectively, as compared with postpartum.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal toxicology studies have been conducted at exposures up to clinical exposure levels with Darunavir alone, in mice, rats and dogs and in combination with ritonavir in rats and dogs.In repeated-dose toxicology studies in mice, rats and dogs, there were only limited effects of treatment with Darunavir. In</p><p>rodents the target organs identified were the haematopoietic system, the blood coagulation system, liver and thyroid. A variable but limited decrease in red blood cell-related parameters was observed, together with increases in activated partial thromboplastin time.</p><p>&nbsp;</p><p>Changes were observed in liver (hepatocyte hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular hypertrophy). In the rat, the combination of Darunavir with ritonavir lead to a small increase in effect on RBC parameters, liver and thyroid and increased incidence of islet fibrosis in the pancreas (in male rats only) compared to treatment with Darunavir alone. In the dog, no major toxicity findings or target organs were identified up to exposures equivalent to clinical exposure at the recommended dose.</p><p>&nbsp;</p><p>In a study conducted in rats, the number of corpora lutea and implantations were decreased in the presence of maternal toxicity. Otherwise, there were no effects on mating or fertility with Darunavir treatment up to 1,000 mg/kg/day and exposure levels below (AUC-0.5 fold) of that in human at the clinically recommended dose. Up to same dose levels, there was no teratogenicity with Darunavir in rats and rabbits when treated alone nor in mice when treated in combination with ritonavir. The exposure levels were lower than those with the recommended clinical dose in humans. In a pre- and postnatal development assessment in rats, Darunavir with and without ritonavir, caused a transient reduction in body weight gain of the offspring pre-weaning and there was a slight delay in the opening of eyes and ears. Darunavir in combination with ritonavir caused a reduction in the number of pups that exhibited the startle response on day 15 of lactation and a reduced pup survival during lactation. These effects may be secondary to pup exposure to the active substance via the milk and/or maternal toxicity. No post weaning functions were affected with Darunavir alone or in combination with ritonavir. In juvenile rats receiving Darunavir up to days 23-26, increased mortality was observed with convulsions in some animals. Exposure in plasma, liver and brain was considerably higher than in adult rats after comparable doses in mg/kg between days 5 and 11 of age. After day 23 of life, the exposure was comparable to that in adult rats. The increased exposure was likely at least partly due to immaturity of the drug-metabolising enzymes in juvenile animals. No treatment related mortalities were noted in juvenile rats dosed at 1,000 mg/kg Darunavir (single dose) on day 26 of age or at 500 mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and toxicity profile were comparable to those observed in adult rats.</p><p>Due to uncertainties regarding the rate of development of the human blood brain barrier and liver enzymes, Darunavir with low dose ritonavir should not be used in paediatric patients below 3 years of age.</p><p>&nbsp;</p><p>Darunavir was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks. Daily doses of 150, 450 and 1,000 mg/kg were administered to mice and doses of 50, 150 and 500 mg/kg were administered to rats. Dose-related increases in the incidences of hepatocellular adenomas and carcinomas were observed in males and females of both species. Thyroid follicular cell adenomas were noted in male rats. Administration of Darunavir did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats. The observed hepatocellular and thyroid tumours in rodents are considered to be of limited relevance to humans. Repeated administration of Darunavir to rats caused hepatic microsomal enzyme induction and increased thyroid hormone elimination, which predispose rats, but not humans, to thyroid neoplasms. At the highest tested doses, the systemic exposures (based on AUC) to Darunavir were between 0.4- and 0.7-fold (mice) and 0.7- and 1-fold (rats), relative to those observed in humans at the recommended therapeutic doses.</p><p>&nbsp;</p><p>After 2 years administration of Darunavir at exposures at or below the human exposure, kidney changes were observed in mice (nephrosis) and rats (chronic progressive nephropathy).</p><p>&nbsp;</p><p>Darunavir was not mutagenic or genotoxic in a battery of <em>in vitro </em>and <em>in vivo </em>assays including bacterial reverse mutation (Ames), chromosomal aberration in human lymphocytes and <em>in vivo </em>micronucleus test in mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Darunavir Tablets 400 mg:</em> Cellulose, Microcrystalline, Hydroxypropylcellulose, Crospovidone, Silica Colloidal Anhydrous, Magnesium Stearate, OPADRY&reg; II Complete Film Coating System 85F93273 ORANGE and Purified Water</p><p><em>Darunavir Tablets 600 mg: </em>Cellulose, Microcrystalline, Hydroxypropylcellulose, Crospovidone, Silica Colloidal Anhydrous, Magnesium Stearate, OPADRY&reg; II Complete Film Coating System 85F13962 ORANGE <em>&nbsp;</em>and Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 24 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>60&rsquo;s count (HDPE Container)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
Aurobindo Pharma Limited, Unit-X,
Plot No.l6, APIIC, Multi Products SEZ,
Menakuru Village, Naidupeta Mandal,
S.P.S.R. Nellore District,
Andhra Pradesh, India

Marketing Authorization Holder:
Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>